Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
Treatment process involving the injection of fluid into an organ or tissue.
Unstable isotopes of nitrogen that decay or disintegrate emitting radiation. N atoms with atomic weights 12, 13, 16, 17, and 18 are radioactive nitrogen isotopes.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
The ratio of alveolar ventilation to simultaneous alveolar capillary blood flow in any part of the lung. (Stedman, 25th ed)
The circulation of blood through the CORONARY VESSELS of the HEART.
The circulation of the BLOOD through the LUNGS.
Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.
The flow of BLOOD through or around an organ or region of the body.
Tomography using radioactive emissions from injected RADIONUCLIDES and computer ALGORITHMS to reconstruct an image.
The creation and display of functional images showing where the blood flow reaches by following the distribution of tracers injected into the blood stream.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
The circulation of blood through the BLOOD VESSELS of the BRAIN.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
The creation and display of functional images showing where the blood is flowing into the MYOCARDIUM by following over time the distribution of tracers injected into the blood stream.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Tumors or cancer of the human BREAST.
The hollow, muscular organ that maintains the circulation of the blood.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the LUNG.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Tumors or cancer of the STOMACH.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Tumors or cancer of the COLON.
Tumors or cancer of the PROSTATE.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
An organoplatinum compound that possesses antineoplastic activity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Elements of limited time intervals, contributing to particular results or situations.
Antimetabolites that are useful in cancer chemotherapy.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A cell line derived from cultured tumor cells.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Organic compounds which contain platinum as an integral part of the molecule.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant epithelial tumor with a glandular organization.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Tumors or cancer of the LIVER.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Tumors or cancer of the URINARY BLADDER.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Tumors or cancer of the UTERINE CERVIX.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Tumors or cancer of the RECTUM.
A subspecialty of internal medicine concerned with the study of neoplasms.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A decrease in the number of NEUTROPHILS found in the blood.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Antibodies produced by a single clone of cells.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
Tumors or cancer of the PERITONEUM.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
Tumors or cancer of the ESOPHAGUS.
A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Transplantation of an individual's own tissue from one site to another site.
Substances used to allow enhanced visualization of tissues.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Organic compounds that contain technetium as an integral part of the molecule. These compounds are often used as radionuclide imaging agents.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
The return of a sign, symptom, or disease after a remission.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
DNA present in neoplastic tissue.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Transplantation between animals of different species.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Surgical procedure to remove one or both breasts.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
An anthracenedione-derived antineoplastic agent.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
A general term for various neoplastic diseases of the lymphoid tissue.
An alkylating agent of value against both hematologic malignancies and solid tumors.
The action of a drug in promoting or enhancing the effectiveness of another drug.
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
Treatment that combines chemotherapy with radiotherapy.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Drugs used to prevent NAUSEA or VOMITING.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
The circulation of the BLOOD through the MICROVASCULAR NETWORK.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
Inorganic compounds which contain platinum as the central atom.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.

L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. (1/241)

PET with L-[1-11C]-tyrosine (TYR) was investigated in patients undergoing hyperthermic isolated limb perfusion (HILP) with recombinant tumor necrosis factor alpha (rTNF-alpha) and melphalan for locally advanced soft-tissue sarcoma and skin cancer of the lower limb. METHODS: Seventeen patients (5 women, 12 men; age range 24-75 y; mean age 52 y) were studied. TYR PET studies were performed before HILP and 2 and 8 wk afterwards. The protein synthesis rates (PSRs) in nanomoles per milliliter per minute were calculated. After final PET studies, tumors were resected and pathologically examined. Patients with pathologically complete responses (pCR) showed no viable tumors after treatment. Those with pathologically partial responses (pPR) showed various amounts of viable tumors in the resected tumor specimens. RESULTS: Six patients (35%) showed a pCR and 11 patients (65%) showed a pPR. All tumors were depicted as hot spots on PET studies before HILP. The PSR in the pCR group at 2 and 8 wk after perfusion had decreased significantly (P < 0.05) in comparison to the PSR before HILP. A significant difference was found in PSR between the pCR and pPR groups at 2 and at 8 wk (P < 0.05). Median PSR in nonviable tumor tissue was 0.62 and ranged from 0.22 to 0.91. With a threshold PSR of 0.91, sensitivity and specificity of TYR PET were 82% and 100%, respectively. The predictive value of a PSR > 0.91 for having viable tumor after HILP was 100%, whereas the predictive value of a PSR < or = 0.91 for having nonviable tumor tissue after HILP was 75%. The 2 patients in the pPR groups with a PSR < 0.91 showed microscopic islets of tumor cells surrounded by extensive necrosis on pathological examination. CONCLUSION: Based on the calculated PSR after HILP, TYR PET gave a good indication of the pathological outcome. Inflammatory tissue after treatment did not interfere with viable tumor on the images, suggesting that it may be worthwhile to pursue TYR PET in other therapy evaluation settings.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (2/241)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Metabolism of [14C]phenol in the isolated perfused mouse liver. (3/241)

A previous report from this laboratory focused on the metabolism of [14C]benzene (BZ) in the isolated, perfused, mouse liver (C. C. Hedli, et al., 1997, Toxicol. Appl. Pharmacol. 146, 60-68). Whereas administration of BZ to mice results in bone marrow depression (R. Snyder et al., 1993, Res. Commun. Chem. Pathol. Pharmacol. 20, 191-194), administration of phenol (P), the major metabolite of BZ, does not. It was, therefore, of interest to determine whether the metabolic fate of P produced during BZ metabolism differed from that of P metabolized in the absence of BZ. Mouse livers were perfused with a solution of [14C]P in both the orthograde (portal vein to central vein) and retrograde (central vein to portal vein) direction to investigate the metabolic zonation of enzymes involved in P hydroxylation and conjugation. Perfusate samples were collected, separated by HPLC, and tested for radioactivity. Unconjugated metabolites were identified by comparing their retention times with nonradiolabeled standards, which were detected by UV absorption. Conjugated metabolites were identified and collected on the basis of radiochromatogram results, hydrolyzed enzymatically, and identified by co-chromatography with unlabeled BZ metabolites. The objective was to compare and quantify the metabolites formed during the perfusion of P in the orthograde and retrograde directions and to compare the orthograde P-perfusion results with the orthograde BZ results reported previously. Regardless of the direction of P perfusion, the major compounds released from the liver were P. phenylgucuronide, phenylsulfate, hydroquinone (HQ), and HQ glucuronide. A comparison of the results of perfusing P in the orthograde versus the retrograde direction showed that more P was recovered unchanged and more HQ was formed during retrograde perfusion. The results suggest that enzymes involved in P hydroxylation are generally closer to the central vein than those involved in conjugation, and that during retrograde perfusion, P metabolism may be limited by the sub-optimal conditions of perfusion. Comparison of the orthograde perfusion studies of P and BZ revealed that a larger percentage of the radioactivity released from the liver was identified as unconjugated HQ after BZ perfusion than after P perfusion. In addition, the amount of radioactivity covalently bound to liver macromolecules was measured after each perfusion and determined to be proportional to the amount of HQ and HQG detected in the perfusate samples.  (+info)

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. (4/241)

An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 microg TNF and 40 microg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24-26 degrees C, anti-tumour effects were lost, whereas temperatures of 38-39 degrees C or 42-43 degrees C resulted in higher response rates. However, at 42-43 degrees C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 microg in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38 degrees C was mandatory. Moreover, the dose of TNF could be lowered to 10 microg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings.  (+info)

Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. (5/241)

Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan (HILP-TM) with or without IFN-gamma is a promising local treatment in patients with locally advanced extremity soft tissue sarcomas (STSs), with response rates of up to 84%. The mechanisms of the treatment response are poorly understood. Here, we determined the HILP-TM-induced changes in mitotic activity, proliferation, and apoptosis in 37 STSs; the additional effect of IFN-gamma; and the association of HILP-TM with treatment response and clinical outcome. On archival material, obtained before and 6-8 weeks after HILP-TM with (n = 15) or without (n = 22) IFN-gamma, the number of mitoses was counted, and the proliferation fraction was determined by immunohistological staining for the proliferation associated Ki-67 antigen (MIB1). Apoptosis was visualized by enzymatic detection of DNA fragmentation (terminal deoxynucleotidyl transferase-mediated nick end labeling method). Clinical and histological response, follow-up status, and survival were recorded. The number of mitoses dropped 57% and proliferation rate decreased with 40% after HILP-TM, whereas the amount of apoptosis after HILP-TM more than doubled as before HILP-TM. The addition of IFN-gamma to HILP-TM did not influence the changes in tumor parameters and did not affect treatment response. A better clinical response to HILP-TM was correlated with high mitotic activity and low amount of apoptosis in tumor samples before HILP-TM. Patients with highly proliferative STS before and after HILP-TM had a relatively poor prognosis. Furthermore, patients who developed distant metastases after HILP-TM had a relatively high number of dividing cells in the tumor remnants after treatment.  (+info)

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. (6/241)

We have shown previously that isolated limb perfusion (ILP) in sarcoma-bearing rats results in high response rates when melphalan is used in combination with tumour necrosis factor alpha (TNF-alpha). This is in line with observations in patients. Here we show that ILP with doxorubicin in combination with TNF-alpha has comparable effects in two different rat sarcoma tumour models. The addition of TNF-alpha exhibits a synergistic anti-tumour effect, resulting in regression of the tumour in 54% and 100% of the cases for the BN175-fibrosarcoma and the ROS-1 osteosarcoma respectively. The combination is shown to be mandatory for optimal tumour response. The effect of high dose TNF-alpha on the activity of cytotoxic agents in ILP is still unclear. We investigated possible modes by which TNF-alpha could modulate the activity of doxorubicin. In both tumour models increased accumulation of doxorubicin in tumour tissue was found: 3.1-fold in the BN175 and 1.8-fold in the ROS-1 sarcoma after ILP with doxorubicin combined with TNF-alpha in comparison with an ILP with doxorubicin alone. This increase in local drug concentration may explain the synergistic anti-tumour responses after ILP with the combination. In vitro TNF-alpha fails to augment drug uptake in tumour cells or to increase cytotoxicity of the drug. These findings make it unlikely that TNF-alpha directly modulates the activity of doxorubicin in vivo. As TNF-alpha by itself has no or only minimal effect on tumour growth, an increase in local concentrations of chemotherapeutic drugs might well be the main mechanism for the synergistic anti-tumour effects.  (+info)

Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. (7/241)

A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM) allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher tumour concentrations of L-PAM. Twenty-four patients with colorectal cancer confined to the liver were treated with L-PAM dosages escalating from 0.5 to 4.0 mg kg(-1). During all IHP procedures, leakage of perfusate was monitored. Duration of IHP was aimed at 60 min, but was shortened in eight cases as a result of leakage from the isolated circuit. From these, three patients developed WHO grade 3-4 leukopenia and two patients died due to sepsis. A reversible elevation of liver enzymes and bilirubin was seen in the majority of patients. Only one patient was treated with 4.0 mg kg(-1) L-PAM, who died 8 days after IHP as a result of multiple-organ failure. A statistically significant correlation was found between the dose of L-PAM, peak L-PAM concentrations in perfusate (R = 0.86, P< or =0.001), perfusate area under the concentration-time curve (AUC; R = 0.82, P<0.001), tumour tissue concentrations of L-PAM (R = 0.83, P = 0.011) and patient survival (R = 0.52, P = 0.02). The peak L-PAM concentration and AUC of L-PAM in perfusate at dose level 3.0 mg kg(-1) (n = 5) were respectively 35- and 13-fold higher than in the systemic circulation, and respectively 30- and 5-fold higher than reported for high dose oral L-PAM (80-157 mg m(-2)) and autologous bone marrow transplantation. Median survival after IHP (n = 21) was 19 months and the overall response rate was 29% (17 assessable patients; one complete and four partial remissions). Thus, the maximally tolerated dose of L-PAM delivered via IHP is approximately 3.0 mg kg(-1), leading to high L-PAM concentrations at the target side. Because of the complexity of this treatment modality, IHP has at present no place in routine clinical practice.  (+info)

A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. (8/241)

There are no satisfactory treatment options for patients with ocular melanoma metastatic to liver, and after liver metastases are identified, median survival is only between 2 and 7 months. Because liver metastases are the sole or life-limiting component of disease in the vast majority of patients who recur, we reasoned that complete vascular isolation and perfusion of the liver might result in clinically meaningful regression of disease. Between September 1994 and July 1999, 22 patients (13 women and 9 men; mean age, 49 years) with ocular melanoma metastatic to liver were treated with a 60-min hyperthermic isolated hepatic perfusion (IHP) using melphalan alone (1.5-2.5 mg/kg, n = 11) or with tumor necrosis factor (TNF, 1.0 mg, n = 11). Via a laparotomy, IHP inflow was via the hepatic artery alone (n = 17) or hepatic artery and portal vein (n = 5) and outflow from an isolated segment of inferior vena cava. Most patients had advanced tumor burden with a mean percentage of hepatic replacement of 25% (range, 10-75%) and a median number of metastatic nodules of 25 (range, 5 to >50). Complete vascular isolation was confirmed in all patients using a continuous intraoperative leak monitoring technique with 131I radiolabeled albumin. There was one treatment mortality (5%). The overall response rate in 21 patients was 62% including 2 radiographic complete responses (9.5%) and 11 partial responses (52%). The overall median duration of response was 9 months (range, 5-50) and was significantly longer in those treated with TNF than without (14 versus 6 months, respectively; P = 0.04). Overall median survival in 22 patients was 11 months. These data indicate that a single 60-min IHP can result in significant regression of advanced hepatic metastases from ocular melanoma. TNF appears to significantly prolong the duration of response.  (+info)

This phase I/II trial studies the safety, best dose and effectiveness of targeted gene therapy combined with isolated limb infusion (ILI) of melphalan and dactinomycin for treating patients with advanced extremity melanoma that cannot be removed by surgery. Adding gene therapy to a standard chemotherapy regimen in the isolated limb may enhance anti-cancer effects by inducing a systemic immune response against the tumor cells ...
TY - JOUR. T1 - Isolated limb infusion for in-transit malignant melanoma of the extremity. T2 - A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. AU - Beasley, Georgia M.. AU - Petersen, Rebecca P.. AU - Yoo, Jin. AU - McMahon, Nicole. AU - Aloia, Thomas. AU - Petros, William. AU - Sanders, Gretchen. AU - Cheng, Tsung Yen. AU - Pruitt, Scott K.. AU - Seigler, Hilliard. AU - Tyler, Douglas. PY - 2008/8. Y1 - 2008/8. N2 - Background: Isolated limb infusion (ILI) is a recently described minimally invasive technique developed in Australia for delivering regional chemotherapy. This study examined the efficacy and toxicity of ILI, compared to hyperthermic isolated limb perfusion (HILP), in treating extremity in-transit melanoma. Methods: Variables from a prospective single institution database of 120 regionally treated melanoma patients (1995-2007) were compared using chi-square analysis. This included 61 consecutive ILI treatments in 58 patients and 59 HILP ...
Trusted Advanced Extremities Sarcoma Specialist serving Hollywood, FL. Contact us at 305-682-1995 or visit us at 4000 Hollywood Blvd., Suite 160N, Hollywood, FL 33021: Atlas Oncology
TY - CHAP. T1 - Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion. AU - Heller, Charles K.. AU - Pingpank, James F.. AU - Libutti, Steven K.. PY - 2009/12/9. Y1 - 2009/12/9. KW - Hepatic arterial infusion (HAI). KW - Inferior vena cava (IVC). KW - Isolated hepatic perfusion and percutaneous hepatic perfusion. KW - Metastatic neuroendocrine tumors (MNET). KW - National institutes of health (NIH). KW - Percutaneous hepatic perfusion. KW - Tumor necrosis factor (TNF). KW - Veno-occlusive disease (VOD). UR - UR - U2 - 10.1002/9781444317053.ch15. DO - 10.1002/9781444317053.ch15. M3 - Chapter. AN - SCOPUS:84948987546. SN - 9781444317053. SN - 9781405179768. SP - 164. EP - 172. BT - Malignant Liver Tumors: Current and Emerging Therapies: Third Edition. PB - Wiley Blackwell. ER - ...
TY - JOUR. T1 - Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. AU - Libutti, Steven K.. AU - Bartlett, David L.. AU - Fraker, Douglas L.. AU - Alexander, H. Richard. PY - 2000. Y1 - 2000. N2 - Background: For a variety of histologies, the liver represents the only or the dominant site of metastatic disease. Regional treatment of the liver has the theoretic advantage of maximizing drug delivery while minimizing systemic toxicity. This article describes the technique of isolated hepatic perfusion using tumor necrosis factor and melphalan under conditions of moderate hyperthermia for the treatment of unresectable liver tumors. Study Design: Fifty patients with biopsy-proved unresectable primary or metastatic cancer to the liver were treated. Isolated hepatic perfusion was performed for 60 minutes under conditions of moderate hyperthermia during a laparotomy with inflow through the ...
As well known, process identification is very important in process control. A Open-loop identification method is proposed in this paper. The identification object is a simulated facility with constant temperature hyperthermic perfusion treatment on bladder cancer. Open-loop step response is applied ,the process input and the resulted output response are logged, and the improved area method is adopted, from which the parameters of a first-order plus dead-time model can be estimated. Based on some PID tuning rule the closed loop experiments have been conducted. The experimental results have shown that the proposed method has good identification accuracy and is insensitive to the noise. Furthermore, the experiments of the closed loop control system have also indicated the design closed loop control system is valid.
In the largest single-institution regional therapy series reported to date, we found that although ILI is effective and well-tolerated, HILP is a more definitive way to control advanced disease.
Patients with pancreatic carcinoma generally have poor prognosis, since it is typically detected too late. Furthermore, it is located near anatomically important structures such as the bile ducts and major blood vessels, which complicates access to the tumor. At the time of diagnosis, only 10% of these tumours are still operable.. For advanced pancreatic carcinoma, chemotherapy only prolongs life expectancy in the range of 2 to 6.5 months. Patients previously treated with radiation and chemotherapy are rarely included in the studies because of their poor prognosis. As a result, very few such studies exist. One study (Author: Berlin JD et al) reports a median survival time (50%) of 6.7 months in a large group of 322 previously treated patients, and a 25% survival period of 10.5 months.. More recent studies of advanced, inoperable pancreatic carcinoma using newer agents could not demonstrate greater than 20-25% survival rate beyond one year. Regional chemotherapy for regionally advanced, ...
BACKGROUND: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan is highly effective in treating limb-threatening soft tissue sarcoma (STS) and other bulky tumors. Because of fear of TNF-associated toxicity, ILP with TNF is not offered to older patients in some cancer centers, although especially in older patients, every attempt to avoid an amputation that may end their independence must be considered. METHODS: Out of 306 TNF-based ILPs, 50 ILPs were performed for limb salvage in 43 patients ,75 years old (range, 75-91 years): 29 STS and 14 melanoma patients. RESULTS: In the STS patients, a response rate of 76% and a limb-salvage rate of 76% were achieved; in the melanoma patients, a 100% response rate and a 93% limb-salvage rate were achieved. Local toxicity was mild. The three postoperative deaths that occurred in the total series of 306 TNF-based ILPs in Rotterdam (,1%) occurred in patients ,75 years old after leakage-free perfusions and were not related to TNF but to ...
The study, conducted over a 22-year period from 1994 to 2016, is the largest one to date of limb preservation using isolated limb infusion for sarcoma. Advocates for [isolated limb infusion] in these patients would argue that, with similar long-term survival data and meaningful overall response rates, patients would much prefer a treatment that preserves the affected extremity to one that does not, Dr. Mullinax said. Isolated limb infusion has historically been used primarily for melanoma of the extremities, and the use of this technique in sarcoma is a novel approach. Sarcoma is a rare type of cancer in the extremities with several different subtypes; the study patients who underwent isolated limb infusion had 17 different subtypes of sarcoma ...
Abstract Purpose: Isolated limb perfusion (ILP) with hyperthermia is an effective treatment for in-transit metastases of malignant melanoma in the extremities. Preclinical studies have shown that hyperthermia may induce an immunogenic death of tumour cells. We therefore decided to study whether ILP may induce tumour-specific immune responses in the clinical setting. Method: The number of Melan-A/Mart-1 specific CD8+ T cells, as well as other phenotypically different immune cells, was recorded in peripheral blood in 12 HLA-A2+ patients with in-transit metastases undergoing hyperthermic ILP with melphalan. Results: All patients underwent ILP without any complication and with an overall response rate of 83%. No substantial changes in the number of circulating T-cells, B-cells, NK-cells or monocytes were observed during follow-up. Four out of 12 patients showed an elevation of Melan-A+ CD8+ T-cells 4 weeks after ILP. Conclusion: We here report our preliminary observations that a small increase in ...
Cavity Circulation Perfusion Thermo-chemotherapy System-HYPERTHERMIC PERFUSION-Cavity Circulation Perfusion Thermo-chemotherapy System
Background There is increasing evidence that tumor hypoxia plays a significant role in the chemoresistance of melanoma, but to our knowledge, real-time tumor oxygenation during isolated limb infusion...
Isolated hepatic perfusion (IHP) is a surgical technique used to treat non-resectable liver cancers. Learn more about this surgical technique.
This talk will focus on the current literature associated with regional limb perfusion and provide technical details of performing regional limb perfusions in the field. In addition, cases and indications of use will be discussed along with common pitfalls or failures seen with the procedure that may lead to a failure in response to treatment. There will be a discussion of the prognosis seen with its use verses without. ...
Regional perfusion therapy can be an option for treating metastases which are cancers that started in one part of the body and have spread to an adjacent part.
Find best value and selection for your MANFRED MANNS EARTH BAND Good Earth UK LP 1974 ILPS search on eBay. World's leading marketplace.
Hello All, A review of the Source Hydration ILPS system. For a while now I have been searching for a hydration system to integrate into my LBT 6094 Slick carrier. The idea was is that the Slick being the base system for all my current rigs I would like to keep the hydration on it. Some requiremen...
Hyperthermic intraperitoneal chemotherapy or HIPEC is a very specialized procedure Fox Chase Cancer Center doctors are using to targeting some rare cancers.
Implementing this complex technique which requires highly skilled centres, increases the survival of patients with ovarian and colon cancer Having a
TY - JOUR. T1 - Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. AU - Pommier, Rodney F.. AU - Moseley, H. Stephens. AU - Cohen, Jordan. AU - Huang, Chu S.. AU - Townsend, Rae Ann. AU - Fletcher, William S.. N1 - Funding Information: From the Division of Surgical Oncology, Oregon Health Sciences University, Portland, Oregon. Supported in part by the American Cancer Society Clinical Fellowship no. 87191, the OregOn Chapter of the Order of the Eastern Star, and the Ladies Auxiliary of the Veterans of Foreign Wars, Portland, Oregon.. PY - 1988/5. Y1 - 1988/5. N2 - Fifty-nine patients with melanoma or soft tissue sarcoma of the extremities underwent hyperthermic isolated limb perfusion utilizing cisplatin and wide local excision. Doses of cisplatin ranged from 0.75 to 2 mg/kg. The mortality and morbidity rates were 0 and 6.8 percent, respectively. Pharmacokinetic studies indicate that ...
Quimioterapia hipertérmica intraperitoneal transoperatória: o que a enfermagem precisa saber [Intraoperative hyperthermic intraperitoneal chemotherapy: what nurses should know]
Tel Aviv Sourasky Medical Center (Ichilov Medical Center) offers Regional Chemotherapy procedures starting from Price on request and it is specialized in Oncology treatments.
Percutaneous hepatic perfusion (PHP) is a minimally invasive treatment that delivers high-dose chemotherapy directly to metastatic melanoma in the liver. Unlike traditional chemotherapy, in which medications circulate throughout the entire body, PHP specifically targets the liver only, which can help reduce the side effects commonly associated with chemo. This approach allows oncologists to treat tumors with much higher doses of chemotherapy than would otherwise be possible when given systemically (through the peripheral veins).. At Moffit Cancer Center, percutaneous hepatic perfusion is offered to treat melanoma that has spread to the liver (as often occurs with ocular melanomas), and select other tumors metastatic to the liver. Prior to recommending this therapy to a patient, our oncologists and interventional radiologists will assess a number of factors, including the following, to ensure that PHP is a suitable option:. ...
Background: Angiosarcomas are rare and aggressive soft-tissue sarcomas. The only potential curative treatment is complete surgical excision. This study reports the outcome of isolated limb perfusion (ILP) with high-dose melphalan and tumour necrosis factor a for locally advanced angiosarcoma. Material and methods: All patients who underwent an ILP for angiosarcomas between 1991 and 2016 in three tertiary referral centres were identified from prospectively maintained data-bases. Results: A total of 39 patients were included, with a median follow-up of 18 months (interquartile range 6.1-60.8). Of these patients, 23 (58.9%) patients had a complete response (CR) after ILP, 10 (25.6%) had a partial response, 4 (10.3%) had stable disease and 2 (5.1%) patients had progressive disease immediately after ILP. A total of 22 patients developed local progression (56.4%), whereas nine (23.1%) developed distant metastases. The patients with CR had a significantly prolonged median local progression-free ...
Definition of in-transit metastasis. Provided by Stedmans medical dictionary and Includes medical terms and definitions.
PURPOSE OF REVIEW: The recent discovery of effective systemic treatments for melanoma has dramatically improved the prognosis for patients with advanced disease. As a result, the multidisciplinary management of melanoma has evolved significantly. In the past decades surgery was reserved for symptomatic palliation in patients with metastatic melanoma. Today surgical treatment of patients responding to systemic therapies has become an integral part of disease control. RECENT FINDINGS: Current efforts are focused on minimizing the morbidity of surgery (laparoscopic inguinal lymph node dissection, selective completion lymphadenectomy) as well as combining surgery with systemic therapy in novel ways (neoadjuvant targeted and/or immunotherapy, isolated limb infusion/perfusion with systemic immunotherapy ...
...NEW YORK Feb. 19 /- Delcath Systems Inc. ...(Logo: ...,Dr.,James,F.,Pingpank,to,Present,at,Leading,Regional,Therapies,Conference,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients Limbs from Amputation (March 16, 2017) Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to the cancerous region can preserve... Continue Reading. ...
This graph shows the total number of publications written about Chemotherapy, Cancer, Regional Perfusion by people in this website by year, and whether Chemotherapy, Cancer, Regional Perfusion was a major or minor topic of these publications ...
Less than four days ago, a young Australian woman died of a very rare type of cancer. Most of my American and probably many of my European readers have never heard of her, but in Australia she had become quite famous over the last seven years as a major proponent of natural health. Her name was Jess Ainscough, but, like a certain.... ...
When treating confined melanoma regional perfusion therapy can be a treatment option for tumors that are confined to a single organ or region of the body.
2012-005748-12Resección D2 y HIPEC (quimioperfusión intraperitoneal hipertermica) en carcinoma gástrico localmente avanzado.Fundación Jiménez DíazInvest...
Hello fellow practitioners!. I have heard from many of you that you are interested in using the ILP Kit to facilitate a local practice group, and are interested in some best practices. Well, I figured that instead of having many separate conversations, lets focus the discussion here for all to see and benefit from. I will be moderating this forum by encouraging people to participate, offering my perspectives and knowledge from working at I-I, and also listening to what you have to say so I can incorporate that feedback into future developments.. I know of a few people that have been facilitating a group already, and have asked some of them to share their process and experiences here. If you have done the same, please share as well. Wed love to hear about what you did, what worked best, what didnt work so well, any questions you are still considering, etc. Also, I would suggest that if youd like to make a post on this, please start a new thread that includes where youre from. That way we can ...
明躍國際健康科技股份有限公司 產品面:|br /|(1)Intelli Key:應用螢光指示燈之專利技術,自動指引使用者操作跑步機及設定運動程式,以免使用者陷入一堆按鍵而不知所措,並避免操作錯誤,輕鬆使用無負擔;|br /|(2)IHP:應用USB及藍芽之3C通訊標準介面,以結合3C產品,連接IHP健康管理系統,可讀取、儲存及傳輸運動資訊,並可以手機/平板電腦/NB控制跑步機,隨時檢視/傳輸運動結果,並結合專業運動教練及醫療人員,設計個人化之運動處方,隨時更新運動處方,使運動更科學有效;|br /|(3)Intelli Step:應用步數計次之專利技術,提供使用者計步之附加功能,再結合個人化專屬網站之IHP健康管理系統,便能使日常生活之步行管理及卡路里計算更精準、更方便;|br /|(4)Intelli Guard:應用跑步機運轉之控制方法之專利技術,當控制系統偵測無人在機台上時
Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in patients with peritoneal carcinomatosis of colorectal origin. Animal models are important in the evaluation of new treatment modalities. The purpose of this study was to devise an experimental setting which can be routinely used for the investigation of HIPEC in peritoneal carcinomatosis. A new peritoneal perfusion system in tumor bearing rats were tested. For this purpose CC531 colon carcinoma cells were implanted intraperitoneally in Wag/Rija rats. After 10 days of tumor growth the animals were randomized into three groups of six animals each: group 1: control (n = 6), group 2: HIPEC with mitomycin C in a concentration of 15 mg/m2 (n = 6), group III: mitomycin C i.p. as monotherapy in a concentration of 10 mg/m2 (n = 6). After 10 days, total tumor weight and the extent of tumor spread, as classified by the modified Peritoneal Cancer Index (PCI), were assessed by autopsy of the animals. No postoperative
To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.. Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.. The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.. ...
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an appropriate treatment for select patients with peritoneal carcinomat
A review of 60 consecutive patients with peritoneal carcinomatosis who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC)-sometimes called hot chemotherapy-found 0% mortality and 33% morbidity, with a significant reduction of grade III/IV morbidity, perioperative transfusion, and reintervention rate after 20 procedures. Reporting their results in the Archives of Surgery,1 physicians at the Institut Paoli-Calmettes and Université de la Méditerranée in Marseille, France, noted that the introduction of the HIPEC program was successful because of the surgical teams prior experience in cytoreductive and cancer operations.. Learning Curve. In an accompanying editorial, Nita Ahuja, MD, agreed: The message that we can heed here is that experience matters. In a follow-up interview with The ASCO Post, Dr. Ahuja said that there are cytoreduction-with-HIPEC programs with experienced physicians at several centers in the United States (see sidebar). These ...
U.S., April 14 -- registry received information related to the study (NCT03111069) titled Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children on April 6. Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of heated doxorubicin that can be given to patients during surgery with abdominal tumors. The safety of this drug will also be studied. Study Start Date: Study Type: Interventional Condition: Malignant Neoplasms of Mesothelial and Soft Tissue Rhabdomyosarcoma, Pelvic Rhabdomyosarcoma, Abdominal Intervention: Procedure: Abdominal Surgery Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease). Unresectable Intra-Abdominal/Pelvic Tumors Group: ...
A recent Phase I clinical trial reported encouraging survival data with respect to the use of maximal cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC) using pegylated liposomal doxorubicin (PLD)(e.g., Doxil™) to treat patients with advanced intra-abdominal, gastrointestinal and gynecological malignancies. HIPEC is used in conjunction with surgery and chemotherapy to treat patients with gastrointestinal tract…
TY - JOUR. T1 - Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?. AU - Baratti, Dario. AU - Kusamura, Shigeki. AU - Iusco, Domenico. AU - Cotsoglou, Christian. AU - Guaglio, Marcello. AU - Battaglia, Luigi. AU - Virzì, Salvatore. AU - Mazzaferro, Vincenzo. AU - Deraco, Marcello. PY - 2018/9. Y1 - 2018/9. N2 - BACKGROUND: Survival improvements have been reported in selected patients affected by colorectal peritoneal metastases who were undergoing cytoreductive surgery with intraperitoneal hyperthermic chemotherapy. Treatment of peritoneal metastases associated with extraperitoneal disease is still controversial.OBJECTIVE: We assessed the prognostic impact of a history of extraperitoneal disease that was curatively treated either at the same time as or before the onset of peritoneal metastases.DESIGN: We reviewed 2 prospective databases. Peritoneal involvement was ...
Abstract: Advancements in medical technology coupled with a more thorough comprehension of oncologic diseases has resulted in a burgeoning number of aggressive treatment options available to cancer patients and a gradual loosening of the association between cancer and timely death. With the advent of extended life expectancies, however, the need to investigate the human and overall life impact of cancer diseases and treatments has increased dramatically (Langenhoff et al., 2001). This need to examine considerations of quality of life becomes even more essential in the context of high-risk treatments, such as cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC), an extensive procedure offered to select candidates with peritoneal carcinomatosis from a variety of primary origins (Levine et al., 2007). A biopsychosocial model of research and clinical care (e.g. Wilson & Cleary, 1995) underscores the many levels and interrelationships of clinical, demographic, and ...
HIPEC is an aggressive, novel surgical treatment reserved for patients with peritoneal carcinomatosis. It combines extensive removal of cancers, known as surgical cytoreduction, with the intraoperative introduction of chemotherapeutic drugs into the peritoneal cavity at a temperature several degress above normal body temperature. The abdominal cavity is perfused for about 90 minutes, thereby exposing potential microscopic residual cancer cells directly to the synergistic effects of hyperthermia (heat), and cytotoxic agents.. HIPEC is resource-intensive and requires extraordinary surgical and multidisciplinary cooperation. As such, only a few centers nationwide offer patients this option. The Feist-Weiller Cancer Center is the only cancer center in Louisiana that offers HIPEC presently.. HIPEC is used to treat the following types of cancers in its advanced and recurrent stages:. ...
Aims and objectives.To study patients descriptions of their health after cytoreductive surgery (CRS) before discharge.. Background. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) affects the patients recovery. The hospital stay is long, and it is important to study how patients experience their health postoperatively.. Design. Qualitative descriptive design.. Methods. Between January-May 2012, individual interviews were conducted with 20 patients in a university hospital in cen- tral Sweden using a semi-structured interview guide. Data were analysed using qualitative content analysis.. Results. Three themes (a process, body and mind, and support) and nine categories emerged. The surgery was described as a turning point, followed by a period of hope and thankfulness. Nevertheless, patients had difficulty taking in their positive feelings because they were overwhelmed by their bodily ailments. Despite the patients descriptions of being on an emotional roller ...
Discussion: The infection rate in our centre compared to previous studies of comparable patients was matching. Effective management of postoperative infections should be considered, and identified risk factors in this study can help to focus on effective prevention and treatment strategies. PMID: 31467552 [PubMed]...
The heated chemotherapy solution is continuously circulated throughout the abdominal cavity. So that the cavity is uniformly exposed to heat and chemotherapy. The combination of heat and chemotherapy causes the solution to kill microscopic cancer cells. Gentle shaking applied to the abdomen to help the solution distributed to all surfaces within the abdomen ...
This trial will evaluate the safety and effectiveness of autologous alpha-type-1 polarized dendritic cell (alpha-DC1) vaccines (patients autologous alpha-DC1s loaded with autologous tumor material), combined with a systemic chemokine modulation regimen [CKM; intravenous rintatolimod (TLR3 ligand, a derivative of Poly-I:C) + intravenous interferon-alfa + oral celecoxib] as adjuvant therapy, after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), in patients with peritoneal surface malignancies (PSM), including but not limited to malignant peritoneal mesothelioma and peritoneal carcinomatosis (PC) of appendiceal and colorectal origin.. All patients judged to have peritoneal surface malignancy and considered able to be cytoreduced to Peritoneal Cancer Index (PCI) Completeness of Cytoreduction (CC) score of 1 or less will undergo CRS + HIPEC. Postoperative immunotherapy will start at least 4 weeks after CRS + HIPEC.. Immunotherapy regimen will include four cycles of ...
TY - JOUR. T1 - A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. AU - Yan, Tristan D.. AU - Black, Deborah. AU - Sugarbaker, Paul H.. AU - Zhu, Jacqui. AU - Yonemura, Yutaka. AU - Petrou, George. AU - Morris, David L.. PY - 2007/10. Y1 - 2007/10. N2 - Background: The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer. Methods: Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis. Results: Thirteen reports of randomized controlled trials (RCTs) were ...
Splenectomy is an independent risk factor for poorer perioperative outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an analysis of 936 procedures
The imaging method called positron emission tomography (PET) using the radioactive tracer molecule 18F-FDG is a valuable way to both diagnose and track the progression of malignant peritoneal mesothelioma. Nuclear medicine researchers at a Hospital in Barcelona, Spain reviewed the diagnostic and treatment records of 60 people with malignant peritoneal mesothelioma, a form of mesothelioma that spreads on the membrane lining the walls of the abdomen. The study subjects included 34 women and 26 men with a mean age of 53. All the patients in the study had had multiple 18-F-FDG-PET scans to diagnose or track their cancer. Eleven of the studied patients had an FDG-PET scan prior to receiving treatment. In all cases, the scans showed characteristic mesothelioma disease … Continue reading Tracking Mesothelioma with FDG-PET » ...
SOUSA, Susana Marques de et al. Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge. GE Port J Gastroenterol [online]. 2020, vol.27, n.3, pp.197-202. ISSN 2341-4545. Introduction: Malignant peritoneal mesothelioma (MPM) is a rare malignancy of the mesothelial cells in the peritoneum. The best-defined risk factor is asbestos exposure, but germline mutations in BAP1 also increase susceptibility to this tumor. The diagnosis of MPM is challenging since clinical manifestations are often nonspecific. Case Presentation: We describe a case of MPM in a 53-year-old former construction worker with prior asbestos exposure. The clinical presentation was a 3-month history of dyspeptic complaints. As initial workup, abdominal ultrasound and upper gastrointestinal endoscopy were performed. Chronic gastritis due to Helicobacter pylori was detected, which was promptly treated but without symptom relief. Abdominal ...
Define L-phenylalanine mustard. L-phenylalanine mustard synonyms, L-phenylalanine mustard pronunciation, L-phenylalanine mustard translation, English dictionary definition of L-phenylalanine mustard. n a drug, C13H18Cl2N2O2, used to treat myeloid leukaemia Noun 1. melphalan - antineoplastic drug used to treat multiple myeloma and some other malignancies...
Researchers at Roswell Park Cancer Institute (RPCI) have determined that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CS/HIPEC), a complex procedure to treat advanced abdominal cancers, can be done safely, and may be an effective therapy for select patients. Study results are published in the June issue of Cancer Medicine.
The SPRinT team sees patients with a wide spectrum of cancer types as peritoneal surface malignancies can arise from various organs. They can arise primarily from the peritoneum (e.g. mesothelioma, primary peritoneal cancer) or from the spread of a primary cancer (e.g. colorectal, appendix, stomach, ovary, hepatobiliary). Our team has extensive experience in treating these varieties of cancer from early to advanced stages. Previously regarded as fatal, peritoneal disease of all histological subtypes can now be successfully treated to achieve good outcomes for patients. Our multidisciplinary clinics offer a one-stop service for the evaluation and surgical management of these patients. In conjunction with our medical oncologists, we provide a comprehensive range of treatments for patients with peritoneal disease, including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The SPRinT team has been performing CRS and HIPEC since 2001 and currently, has one of the ...
Professor David L Morris is a Clinical Academic of the St George & Sutherland Clinical School, located on the grounds of St George Hospital. Research Interests: Surgical Oncologist, principally interested in treating metastatic cancer. Large databases of peritoneal and liver surgery Peritoneal and lung metastases. Basic cancer research lab, cell biology and drug development. Three drugs from our laboratory are under development: aminoacetonitrile pathway inhibitor, benzimidazole carbamate VEGF inhibitor and enzyme combination treatment for mucin-containing cancers. Also tumour ablation - bipolar RFA probe developer.. Broad Research Areas: Cancer Research. Qualifications:. MB, ChB, FRCS, FRCSE, MD, PhD, FRACS Specific Research Keywords:. Peritonectomy, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, RF Ablation, Albendazole, Bromelain, N-acetylcysteine, MUC, Monepantel. ILP/Honours research projects available for 2016:. Peritoneal cancers, effect of targeted anti-mucin ...
The data were collected in the Medical Spectrum Twente, a large community teaching hospital in the regional capital of a foremost rural area in the eastern part of the Netherlands. It functions as a regional referral center for liver and lung surgery, but has no facilities for the treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy (HIPEC).. The study design is a prospective observational cohort study evaluating the outcome of routine staging with abdominal CT concerning the ability to find liver metastases (LM), peritoneal carcinomatosis (PC) and T4-stage in colon cancer (LACC). All patients in our hospital who where treated for CRC from January 2007 till December 2009 were included in the analysis; all surgical patients with CRC in the study hospital were prospectively registered in a database designed for colorectal surgery, including patient characteristics, staging and surgical procedures, the clinical M stage and pathological TNM stage, post-operative ...
Feist-Weiller Cancer Center. View Dr. Chus CV. Dr. Quyen Chu is a Professor of Surgery and Chief of the Division of Surgical Oncology at LSUHSC at Shreveport. He joined LSUHSC at Shreveport in 2002 after completing a clinical fellowship in surgical oncology at Roswell Park Cancer Institute in Buffalo, NY.. Dr. Chus clinical interests include the management of patients with cancer of the gastrointestinal tract (esophagus, stomach, liver, bile ducts, pancreas, colon and rectum), breast cancer, melanoma, thyroid and parathyroid tumors, and soft tissue tumors (retroperitoneal tumors and extremity sarcomas). He has been instrumental in establishing two life-saving programs: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) program for advanced abdominal malignancies and mammosite for breast cancer patients. He has also helped in the development of novel therapies, such as gene therapy, to treat patients with advanced solid malignancies.. Dr. Chu has coauthored more than 70 publications and six book ...
BACKGROUND: While liver resection (LR) and cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) are commonly performed for
He also specializes in the treatment of peritoneal-based malignancies using hyperthermic intraperitoneal chemotherapy (HIPEC). Multidisciplinary GI Conference/Clinic. For patients with gastrointestinal cancers, we bring together a highly specialized team to rapidly evaluate each case and develop a consensus treatment plan. This is called a multidisciplinary conference. The purpose is to help speed up the time from diagnosis to treatment. This comprehensive conference includes surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, a genetic counselor, clinical trials nurses, social workers, dietitians and a clinic coordinator.. Patients in the Multidisciplinary Gastrointestinal Oncology Clinic receive comprehensive therapy coordinated within a single clinic, resulting in the delivery of personalized clinical care. We also provide a caring and supportive environment with the help of our nursing staff, nurse practitioners, social workers and dietitians.. ...
Background: Pancreatic cancer is the fourth leading cause of cancer related death in the Western world. At time of diagnosis, 20% of patients present with a resectable tumour, 40% with an irresectable locally advanced tumor (without metastases) and 40% with metastatic disease. The median survival of patients with irresectable locally advanced pancreatic cancer is only 6 months. Currently, there is no effective treatment for these patients Importance: There is an urgent need for new therapeutical options in pancreatic adenocarcinoma. Radiofrequency ablation (RFA) is a technique that has been demonstrated to be effective in the treatment of several irresectable tumours such as liver and lung neoplasms. RFA produces local tumour destruction from an electrode implanted directly into the tumour causing frictional heating. Objective: To evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUSRFA) plus conventional treatment (chemotherapy ± radiotherapy) improves overall survival in ...
DUGi: Viewing Item from repository Recercat: Background: Pancreatic cancer is the fourth leading cause of cancer related death in the Western world. At time of diagnosis, 20% of patients present with a resectable tumour, 40% with an irresectable locally advanced tumor (without metastases) and 40% with metastatic disease. The median survival of patients with irresectable locally advanced pancreatic cancer is only 6 months. Currently, there is no effective treatment for these patients Importance: There is an urgent need for new therapeutical options in pancreatic adenocarcinoma. Radiofrequency ablation (RFA) is a technique that has been demonstrated to be effective in the treatment of several irresectable tumours such as liver and lung neoplasms. RFA produces local tumour destruction from an electrode implanted directly into the tumour causing frictional heating. Objective: To evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUSRFA) plus conventional treatment (chemotherapy ±
SPIS TREŚCI 2014, Tom XXXVI, Nr 216, CZERWIEC CONTENTS 2014, VOL XXXVI, No. 216, JUNE ARTYKUŁ REDAKCYJNY / EDITORIAL Chronowska J., Łabuzek K., Kukla U., Lekstan A., Okopień B.: 365 Dootrzewnowa chemioterapia perfuzyjna w hipertermii jako nowy sposób leczenia przerzutów nowotworowych do otrzewnej Hyperthermic intraperitoneal chemotherapy as a new way of peritoneal metastases treatment PRACE ORYGINALNE / ORIGINAL PAPERS Pawełczak E., Gaszyński T.: 369 Występowanie nadciśnienia tętniczego w społeczności miejskiej a promowanie zachowań prozdrowotnych The prevalence of hypertension among the urban community and promoting healthy behaviors Jerzykowska S., Cymerys M., Roszak M., Wysocka E., Michalak S., Pupek-Musialik D.: 373 Analiza wpływu krótkotrwałego wysiłku fizycznego na wybrane parametry funkcji śródbłonka naczyniowego oraz sztywność naczyń krwionośnych u młodych i zdrowych mężczyzn The analysis of the influence of short term physical effort on selected
Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.
Normothermic ex vivo limb perfusion is superior to subnormothermic and hypothermic preservation - A randomised, preclinical transplant study ...
Intraperitoneal chemotherapy in the largest biology dictionary online. Free learning resources for students covering all major areas of biology.
Percutaneous hepatic perfusion (PHP) is a regionalized, minimally-invasive approach to cancer treatment currently undergoing Phase II and Phase III clinical testing. PHP treats a variety of hepatic tumors by isolating the liver and exposing the organ to high-dose chemotherapy. As demonstrated in clinical trials, patients treated by PHP can tolerate much higher doses of chemotherapeutic agents than those receiving traditional systemic chemotherapy without increased toxicities. Using a system of catheters and filters, PHP isolates the liver from the circulatory system and infuses a chemotherapeutic agent directly to the liver via the hepatic artery. The venous effluent from the liver is then filtered outside of the body and the filtered blood is returned into the jugular vein. PHP is a repeatable procedure and can be performed in an operating room or a radiology suite under local or general anesthesia. Delcath Systems Business Wire Delcath Systems, Inc. Pingpank JF, Libutti SK, Chang R, et al. ...
Peritoneal metastasis of gastric cancer is still a dismal disease and has extremely poor prognosis even with systemic intensive chemotherapy. We have
Peritoneal Carcinomatosis is a tumor spreading from its original site into the peritoneum (a membrane lining the abdominal cavity). Discover HIPEC
TY - CHAP. T1 - Trattamento integrato delle carcinosi peritoneali. T2 - esperienza preliminare.. AU - De Rosa, B.. AU - Valle, M.. AU - Cavaliere, F.. AU - Federici, O.. AU - Sperduti, I.. AU - Garofalo, A.. PY - 2005. Y1 - 2005. N2 - A prospective study has been carried on 37 patients, 35 of them affected by peritoneal carcinomatosis from ovarian (16), appendiceal (7), colorectal (5), mesothelial (4), gastric (3) primary and 2 affected by sarcomatosis. Mean PCI was 22 (median, 22). Eighty-five percent of the patients presented debilitating ascites associated in 23% to initial symptoms of intestinal obstruction. All the patients have been treated with peritonectomy and intraoperative hyperthermic chemoperfusion and CC 0-1 cytoreduction was achieved in 81%. Major morbidity and mortality was respectively 37.8% and 16.2%, where 5 out 6 deaths recorded in the first 19 months of our experience, representing our learning curve. At a median follow-up of 8 months (range, 1-54), 18 patients are alive and ...
• Regional perfusion has been utilized in the treatment of accessible melanomas for many years. This series of 245 patients, which encompasses over ten years of
Cornelis J. H. van de Velde is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Arian R. van Erkel is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
ConclusionsComplete CRS and HIPEC can be achieved in strictly selected patient with unresectable PM at diagnosis after repeated PIPAC session with palliative intent....
Regional hyperthermia heats a larger part of the body, such as an entire organ or limb. Usually, the goal is to weaken cancer ... Hot chemotherapy drugs are pumped directly into the peritoneal cavity to kill the cancer cells. Whole-body hyperthermia heats ... This may use the same techniques as local hyperthermia treatment, or it may rely on blood perfusion. In blood perfusion, the ... It is typically used to treat metastatic cancer (cancer that spread to many parts of the body). Techniques include infrared ...
... chemotherapy, cancer, regional perfusion MeSH E04.292.451 - extracorporeal membrane oxygenation MeSH E04.292.465 - heart bypass ...
Seidel, Geoffrey D. Part I: Regional Chemotherapy Clinical Studies in Nontraditional Clinical Settings. 10.1188/06.CJON.338-344 ... "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer" at ... as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, ... New Jersey Providence Cancer Center in Portland, Oregon St. Luke's Cancer Center of Bethlehem, Pennsylvania Swedish Medical ...
... limb infusion is a minimally invasive alternative to isolated limb perfusion for delivering high-dose regional chemotherapy to ... 181m on cancer research grants in 2014, and almost 800 cancer patients per week still die of cancer, or over 40,000 Australians ... When local cancer tumours where injected with the vaccine, cancers that had not been injected began to shrink as well, thus ... innovative and specialist cancer drugs in Australia states that the five-year survival rate of patients with advanced cancer is ...
Seidel GD, Locklin J, Muehlbauer PM (June 2006). "Part I: regional chemotherapy clinical studies in nontraditional clinical ... Percutaneous hepatic perfusion (PHP) is a regionalized, minimally-invasive approach to cancer treatment currently undergoing ... PHP treats a variety of hepatic tumors by isolating the liver and exposing the organ to high-dose chemotherapy. As demonstrated ... treated by PHP can tolerate much higher doses of chemotherapeutic agents than those receiving traditional systemic chemotherapy ...
... is also used in veterinary medicine, where is it usually referred to as regional limb perfusion (RLP). It is ... Limb perfusion entry in the public domain NCI Dictionary of Cancer Terms This article incorporates public domain material from ... The main purpose of the isolated limb perfusion technique is to deliver a very high dose of chemotherapy, at elevated ... Regional limb perfusion allows drug dose to be reduced while maintaining therapeutic concentrations at the site of interest, ...
"What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer". ... Finally, to confirm adequate placement and hepatic perfusion, and to rule out extrahepatic perfusion, a dye (fluorescein or ... "A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of ... inadequate perfusion of the entire liver due to the inability to identify an accessory hepatic artery, extrahepatic perfusion ...
"Chemotherapy Delivery Options: Benefits of Regional Therapies". Cancer Treatment Centers of America. 2018-10-17. Retrieved 2019 ... December 2012). "Chemosaturation with Percutaneous Hepatic Perfusion for Unresectable Isolated Hepatic Metastases from Sarcoma ... Cancer Treatment Center of America, Intra-Arterial chemotherapy May, Benjamin J.; Madoff, David C. (June 2012). "Portal vein ... Breast Cancer: for small, solitary breast cancer image guided ablative techniques are used to treat tumors, however their ...
Widespread methods for detection of cancer involve identification of non-neuronal thermoregulation of blood perfusion as well ... The surface of the organ exhibits significant regional temperature variation and often survives thermal extremities that would ... Temperatures above 40 °C are often favourable conditions for receptiveness to chemotherapy and radiotherapy. Raynaud's ... "Cryosurgery in Cancer Treatment". National Cancer Institute. 2005-09-09. Retrieved 2019-06-02. Kuflik, Emanuel G. (1985-11-01 ...
... cancer stem cells appear to exhibit enhanced resistance to radiotherapy and chemotherapy mediated, at least in ... The high permeability and poor perfusion of the vasculature result in a disorganized blood flow within the tumor and lead to ... About three per 100,000 people develop the disease a year, although regional frequency may be much higher. The frequency in ... There is no known method of preventing the cancer. Treatment usually involves surgery, after which chemotherapy and radiation ...
"Intrathecal Chemotherapy for Cancer Treatment , CTCA". Retrieved 22 May 2017. Hajdu SI (2003). "A note from ... Baricity refers to the density of a substance compared to the density of human cerebrospinal fluid and is used in regional ... This decreases total intracranial pressure and facilitates blood perfusion. Homeostasis: CSF allows for regulation of the ... Some anaesthetics and chemotherapy are injected intrathecally into the subarachnoid space, where they spread around CSF, ...
... refractory cancer - regional cancer - regional chemotherapy - regional enteritis - regional lymph node - regional lymph node ... islet cell cancer - islet of Langerhans cell - isoflavone - isointense - isolated hepatic perfusion - isolated limb perfusion ... cancer induction - Cancer Information Service - cancer of unknown primary origin - Cancer stem cell - cancer vaccine - Cancer. ... local cancer - local therapy - localized gallbladder cancer - locally advanced cancer - lometrexol - lomustine - lonafarnib - ...
"Chemotherapy Delivery Options: Benefits of Regional Therapies". Cancer Treatment Centers of America. 2018-10-17. Retrieved 2019 ... As the perfusion to a limb diminishes further pain in the foot can occur even at rest and in fact the tissues of the foot can ... Breast Cancer: for small, solitary breast cancer image guided ablative techniques are used to treat tumors, however their ... "Cryotherapy for Prostate Cancer". Retrieved 2019-11-03. Sabel, Michael S. (July 2014). "Nonsurgical ablation of ...
Among cancers that originate from liver tissue, HCC is the most common primary liver cancer. In the United States, the US ... Loco-regional therapy (also referred to as liver-directed therapy) refers to any one of several minimally-invasive treatment ... Due to the characteristic blood flow pattern of HCC tumors, a specific perfusion pattern of any detected liver lesion may ... Mipsagargin (G-202), has orphan drug designation as a treatment during chemotherapy for HCC. It is a thapsigargin-based prodrug ...
... imaging of the breast for early prediction of response to neoadjuvant chemotherapy and survival outcomes in breast cancer ... Coupled with imaging of cerebral perfusion, researchers can highlight regions of "perfusion/diffusion mismatch" that may ... "Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy". Magnetic ... In head and neck cancers, TIRM has been found to both give high signal in tumor mass, as well as low degree of overestimation ...
"Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer". ... This determines how the further treatment (like surgery, chemotherapy, radiotherapy or targeted drugs etc.) and the best ... Similarly, the MPRAD features in brain stroke demonstrated increased performance in distinguishing the perfusion-diffusion ... July 2017). "Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer". Cancer Research. 77 (14): 3922-3930. doi: ...
The Regional Cancer Center. 2001 Archived October 7, 2009, at the Wayback Machine ... poor perfusion). Thus ischemia in a body part can cause localized anemic effects within those tissues. ... associated with chemotherapy, or associated with renal disease, some clinicians prescribe recombinant erythropoietin or epoetin ... Many type of cancers, including colorectal cancer and cancer of the urinary bladder, may cause acute or chronic blood loss, ...
In case contrast agent has been used to mark the lesion, it will also drain into the regional lymph nodes, which then can be ... Improvements of the C-Arm technology nowadays also enable perfusion imaging and can visualize parenchymal blood volume in the ... 2003). "Performance Characteristics of Different Modalities for Diagnosis of Suspected Lung Cancer *". Chest. 123 (1 Suppl): ... chemotherapy (curative approach) or through chemoembolization / ablation (palliative approach) A hybrid operating room supports ...
Another approach to cancer suppression is through the use of angiogenesis inhibitors to prevent the release of growth factors ... Microencapsulation is a valuable technique for local, regional and oral delivery of therapeutic products as it can be implanted ... 2003). "Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable ... which stimulate neovascularization and restore perfusion in the damaged ischemic heart. An example of this is shown in the ...
... cancer surgery, cancer therapy, pharmacotherapy, phytotherapy, Hindiba, Taxus baccata L, calcium channel blocker Isaac Singer ( ... the first regional jet) Linus Yale Jr. (1821-1868), U.S. - cylinder lock Linus Yale Sr. (1797-1858), U.S. - pin tumbler lock ... organ perfusion pump Frans Wilhelm Lindqvist (1862-1931), Sweden - Kerosene stove operated by compressed air Carl Linnaeus ( ... chemotherapy, sodium hydroxide Alec Reeves (1902-1971), UK - Pulse-code modulation Karl von Reichenbach (1788-1869), Germany - ...
... as might occur following poisoning or cancer chemotherapy), exposure to ionizing radiation, or as a result of an infectious ... In children the presence of cyanosis, rapid breathing, poor peripheral perfusion, or a petechial rash increases the risk of a ... "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a ... The patient is immunocompromised (for example, in AIDS or after chemotherapy);. *The infectious agent is of an uncommon nature ...
... as might occur following poisoning or cancer chemotherapy), exposure to ionizing radiation, or as a result of an infectious ... In children the presence of cyanosis, rapid breathing, poor peripheral perfusion, or a petechial rash increases the risk of a ... GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all- ... in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not ...
The prognosis of brain cancer depends on the type of cancer diagnosed. Medulloblastoma has a good prognosis with chemotherapy, ... Perfusion Weighted Imaging (PWI) and Diffusion Weighted Imaging (DWI) are two MRI techniques that reviews have been shown to be ... "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, ... "Cancer Stat Facts: Brain and Other Nervous System Cancer". National Cancer Institute. 31 March 2019.. ...
"Intrathecal Chemotherapy for Cancer Treatment , CTCA". Retrieved 22 May 2017.. ... This decreases total intracranial pressure and facilitates blood perfusion.[1]. *Homeostasis: CSF allows for regulation of the ... Baricity refers to the density of a substance compared to the density of human cerebrospinal fluid and is used in regional ... Anaesthesia and chemotherapyEdit. See also: Blood-cerebrospinal fluid barrier. Some anaesthetics and chemotherapy are injected ...
Cancers may be treated by surgically removing the tumour, radiotherapy, chemotherapy or combinations thereof, or with the aim ... General anatomy: systems and organs, regional anatomy, planes and lines, superficial axial anatomy, superficial anatomy of ... Pulmonary emboli may be investigated using a ventilation/perfusion scan, a CT scan of the arteries of the lung, or blood tests ... The major risk factor for cancer is smoking. Once a cancer is identified it is staged using scans such as a CT scan and a ...
... cancer, regional perfusion. Chemotherapy, cancer, regional perfusion synonyms, Chemotherapy, cancer, regional perfusion ... cancer, regional perfusion translation, English dictionary definition of Chemotherapy, cancer, regional perfusion. n. 1. The ... treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues. 2 ... Chemotherapy, cancer, regional perfusion - definition of Chemotherapy, cancer, regional perfusion by The Free Dictionary https ...
Determination of Blood Volume and Its Application to Regional Perfusion in Chemotherapy Lead researcher. V C Marshall ... News from Cancer Council Victoria and stories of those affected by cancer. ... Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would ... Cancer is a disease of the cells, which are the bodys basic building blocks. ...
Chemotherapy, Cancer, Regional Perfusion*Chemotherapy, Cancer, Regional Perfusion. *Regional Perfusion Antineoplastic ... Cancer, Regional Perfusion" by people in this website by year, and whether "Chemotherapy, Cancer, Regional Perfusion" was a ... "Chemotherapy, Cancer, Regional Perfusion" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus ... Below are the most recent publications written about "Chemotherapy, Cancer, Regional Perfusion" by people in Profiles. ...
Cancer Treatment. Chemotherapy. Regional Therapy. Surgery. Additional relevant MeSH terms: Layout table for MeSH terms. ... The disease has a marked propensity for loco-regional spread and will be the sole or major site of disease in up to 80% of ... The disease has a marked propensity for loco-regional spread and will be the sole or major site of disease in up to 80% of ... Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability. Acta Med Austriaca. ...
Background In a prior randomized phase II trial comparing hyperthermic isolated limb perfusion (HILP) with four different doses ... Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.CrossRefPubMedGoogle ... Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J Exp Clin Cancer Res. 2004;23:225-31. ... European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. ...
Hyperthermic isolated limb perfusion with melphalan alone is administered as a double perfusion schedule. These two isolates ... CHEMOTHERAPY: At least 1 month since chemotherapy.. ENDOCRINE THERAPY: Not specified.. RADIOTHERAPY: At least 1 month since ... We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. is ... At least 2 months since any regional therapy to the affected extremity.. BIOLOGIC THERAPY: At least 1 month since Biologic ...
Chemohyperthermic peritoneal perfusion had an efficiency for the prophylaxis of recurrence after curative resection of advanced ... gastric cancer, and is indicated for patients with tumor infiltrating beyond serosal layer and node positive tumor. ... Chemotherapy, Adjuvant * Chemotherapy, Cancer, Regional Perfusion* * Female * Gastric Mucosa / pathology * Humans * Hypothermia ... Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized ...
Chemotherapy, Cancer, Regional Perfusion * Humans * Hyperthermia, Induced* * Mitomycin / administration & dosage * Paclitaxel ... The value of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and of additional factors predicting long-term ... Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single ... unfavourable histology and previous chemotherapy were associated with poor outcomes for DFS. There was morbidity of Grade 3 or ...
Chemotherapy, Cancer, Regional Perfusion. *Laparoscopy. *Precancerous Conditions. *Gynecologic Surgical Procedures. * ... or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy ... Primary Peritoneal Cancer or Fallopian Tube Cancer Ovary. A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The ... In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer ...
Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-31.PubMedGoogle Scholar ... Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977;185:555-64PubMedGoogle Scholar ... Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969;129:305-8.PubMedGoogle ... Results of regional isolation perfusion with cytostatics in patients with soft-tissue tumors of the extremities. Cancer. 1989; ...
86 Regional Chemotherapy for Liver Tumors 87 Systemic Chemotherapy for Hepatic Colorectal Cancer: Impact on Surgical Management ... 89 Isolated Hepatic Perfusion for Extensive Liver Cancer Subsection E Treatment: Resection 90A Hepatic Resection: General ... 49 Cancer of the Gallbladder 50A Cancer of the Bile Ducts: Intrahepatic Cholangiocarcinoma 50B Cancer of the Bile Ducts: ... 58A Epidemiology of Pancreatic Cancer. 58B Pancreatic Cancer: Clinical Aspects, Assessment, and Management 59 Pancreatic Cancer ...
Regional hyperthermia heats a larger part of the body, such as an entire organ or limb. Usually, the goal is to weaken cancer ... Hot chemotherapy drugs are pumped directly into the peritoneal cavity to kill the cancer cells. Whole-body hyperthermia heats ... This may use the same techniques as local hyperthermia treatment, or it may rely on blood perfusion. In blood perfusion, the ... It is typically used to treat metastatic cancer (cancer that spread to many parts of the body). Techniques include infrared ...
Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ... Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ... Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ... Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ...
Peritoneal Neoplasms; Hyperthermia, Induced; Chemotherapy, Cancer, Regional Perfusion; Adenocarcinoma; Antineoplastic Combined ... Lymphoma, Non-Hodgkin; Antineoplastic Combined Chemotherapy Protocols; Hemangiopericytoma; Meningioma; Antiretroviral Therapy, ...
Adolescent, Adult, Aged, Antineoplastic Agents/*administration & dosage, Chemotherapy; Cancer; Regional Perfusion, Humans, ... Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian ... Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion. RESULTS ... BACKGROUND: Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients ...
Chemotherapy, Cancer, Regional Perfusion. *Gastrointestinal Neoplasms. *Hyperthermia, Induced. *Peritoneal Neoplasms. *Surgical ... Wilkes - Wilkes Regional Medical Center. HPR- High Point Regional. N/A - Not applicable to services provided at facility and/or ... Wilkes - Wilkes Regional Medical Center. HPR- High Point Regional. N/A - Not applicable to services provided at facility and/or ... A Study of the Effects of Chemotherapy after Surgery in Breast Cancer Patients ...
Chemotherapy. Chemotherapy drugs stop cancer cell growth by either destroying the cells or stopping them from dividing. ... Isolated Limb Perfusion This very rarely used treatment directs a high dose of chemotherapy drugs directly to the soft tissue ... Regional Hyperthermia Therapy. This very rarely used treatment exposes the tissue around the tumor to high temperatures in ... Laryngeal Cancer Treatment Leukemia Treatment Lip & Oral Cavity Cancer Treatment Liver Cancer Treatment Lung Cancers Treatment ...
Chemotherapeutic Regional Perfusion. Chemotherapeutic regional perfusion (also called isolated limb perfusion) is a technique ... allowing your immune system to better attack the cancer cells, block the cancer cells from growing, or deliver chemotherapy or ... Skin cancer is cancer that starts in the skin cells. Skin cancers are divided into two major groups: *Nonmelanoma skin cancer, ... Skin cancer; Squamous cell cancer; Basal cell cancer; Actinic keratosis; Nonmelanoma skin cancer An in-depth report on the ...
Isolated limb perfusion: A procedure that sends chemotherapy directly to an arm or leg in which the cancer has formed. The flow ... Regional chemotherapy Clinical trials are studying ways to improve the effect of chemotherapy on tumor cells, including the ... Chemotherapy Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells ... systemic chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated. ...
Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal ... Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO (1993) Regional therapy of melanoma. Eur J Cancer 29A(4):606-612PubMedCrossRef ... Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: ... Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80(1- ...
... methylation could be an important factor in determining which melanoma patients should receive melphalan regional chemotherapy. ... Methylation of the genes promoter has been associated with several cancer types, including colorectal cancer, lung cancer, ... Title: MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study. ... Alkylating agents are potent carcinogens that can result in cell death, mutation and cancer. The protein encoded by this gene ...
Locoregional chemotherapy via intra-arterial perfusion or chemoemoblization takes advantage of the increasing local drug ... Experimental: regional interventional chemotherapy group Procedure: regional interventional chemotherapy group The patients in ... Regional Versus Systemic Chemotherapy in the Treatment of Unresectable Pancreatic Cancer. The safety and scientific validity of ... Systemic chemotherapy with cytotoxic drug is of limited effectiveness in advanced pancreatic cancer patients. Gemcitabine has ...
But if there is no evidence of cancer in the sentinel node, patients are spared from additional lymph node surgery. ... In 1991, I introduced lymph-node mapping and sentinel lymph-node biopsy for melanoma and other selected skin cancers. Together ... If a biopsy of the sentinel node indicates cancer spread, the surrounding lymph nodes are removed. ... "Regional chemotherapy of melanoma." Brady MS, Coit DG. In: Regional Chemotherapy Clinical Research and Practice. Markman M, ed ...
Evidence-based recommendations on chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for ... Regional hepatic arterial delivery of high-dose chemotherapy with isolated hepatic perfusion used to be done using open ... Liver cancers Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic ... Treatment for primary or metastatic liver cancer depends on the location and stage of the cancer and how well liver function is ...
... our cancer care experts have years of experience treating the most common to the rarest forms of gastrointestinal cancers. From ... we offer long-term infusion chemotherapy treatments and regional perfusion chemotherapy.. *Cryoablation - This procedure ... Whether you have esophageal cancer, pancreatic cancer, liver cancer or some other type of gastrointestinal cancer, we offer a ... Gastrointestinal cancer screening options for early detection. With any type of cancer, early detection is critical to ...
... study was to determine the effect of mild hyperthermia on tumor response and angioneogenesis in an isolated limb perfusion ... Creech OJ, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: Regional perfusion utilizing an extracorporal circuit. Ann ... Prerequisites for effective isolated limb perfusion using tumor necrosis factor alpha and melphalan in rats. Br J Cancer. 1999 ... Cancer. 1992, 70: 2192-202.View ArticlePubMedGoogle Scholar. *. Ichihara F, Kono K, Sekikawa T, Matsumoto Y: Surgical stress ...
Isolated limb perfusion: A procedure that sends chemotherapy directly to an arm or leg in which the cancer has formed. The flow ... Regional chemotherapy. Clinical trials are studying ways to improve the effect of chemotherapy on tumor cells, including the ... Chemotherapy. Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the ... systemic chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated. ...
Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant?. Lorenz, M., Heinrich, S., Staib-Sebler, ... J. Cancer (2000) [Pubmed]. *Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. Lorenz, M ... Regional chemotherapy. Lorenz, M., Heinrich, S. Hematol. Oncol. Clin. North Am. (2002) [Pubmed] ... Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. Lorenz, M., Heinrich, S., ...
Gynecologic cancers: Indications for: COSMEGEN As a single agent or as part of a combination chemotherapy regimen for post- ... Regional perfusion (in combination with melphalan): 50mcg/kg once for lower extremity or pelvis; 35mcg/kg once for upper ... Prostate and other male cancers: Indications for: COSMEGEN In combination with other chemotherapy and/or multi-phase treatment ... Bladder, kidney, and other urologic cancers: Indications for: COSMEGEN In combination with other chemotherapy and/or multi- ...
  • In a prior randomized phase II trial comparing hyperthermic isolated limb perfusion (HILP) with four different doses of tumor necrosis factor alpha (TNF-α), no dose effect was detected for response, but systemic toxicity was far lower with low-dose TNF-α. (
  • Fifty-one patients had received systemic chemotherapy before HILP. (
  • Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow rate adjustment. (
  • Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. (
  • In metastatic melanoma patients, different drug delivery modalities such as systemic, loco-regional and intratumoral are under investigation. (
  • Systemic chemotherapy with cytotoxic drug is of limited effectiveness in advanced pancreatic cancer patients. (
  • Locoregional chemotherapy via intra-arterial perfusion or chemoemoblization takes advantage of the increasing local drug concentrations and reducing systemic toxicities. (
  • In this study, the investigators hypothesis that artery infusion chemotherapy had a better antitumor effect than systemic chemotherapy. (
  • Treatment options include surgical resection, thermal ablation, systemic chemotherapy, transarterial chemoembolisation and selective internal radiation therapy. (
  • This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma in patients who (1) are not candidates for targeted therapy and (2) are not candidates for an immune checkpoint inhibitor. (
  • This technique delivers chemotherapy directly to the affected areas of the abdomen, increasing its effectiveness and reducing the complications of systemic chemotherapy. (
  • This combination of local chemotherapy with systemic checkpoint blockade inhibitor resulted in a response rate of 85% at 3 months (62% complete and 23% partial response rate) and a 58% progression-free survival at 1 year. (
  • This isolation limits toxicities which result from systemic chemotherapy treatments. (
  • In this study, we used our well-established ILP experimental model to evaluate whether the synergistic effect between the two drugs seen in the systemic setting, could further improve response rates in a loco-regional setting. (
  • Characterized by wide dissemination of carcinomas through the peritoneum 2,3 , peritoneal carcinoma secondary to conventional gastrointestinal neoplasms leads to a median survival of 5.2 months in advanced colorectal cancer and 3.1 months in advanced gastric cancer 4 .Until recently, conventional treatment consisted of systemic chemotherapy, or just palliative care. (
  • According to numerous studies, this approach lets physicians increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes when treating illnesses such as cancer with chemotherapy. (
  • This method of local delivery may cause tumors that were previously unresponsive to systemic chemotherapy to respond. (
  • Early perfusion changes within 1 week following systemic therapy measured by DCE-MRI may aid in the prediction of the clinical outcome in patients with advanced HCC. (
  • DCE-MRI is helpful to evaluate perfusion changes of HCC after systemic treatment. (
  • Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. (
  • Cancer is one of the systemic diseases with the higher socioeconomic impact worldwide in terms of costs, loss of productivity and quality of life. (
  • Surgical resection and postoperative systemic treatment are common strategies, but cancers in more advanced stages often do not respond to this approach. (
  • The simplest way of giving a chemotherapy dose is intravenously, through a slow infusion or a bolus injection (systemic chemotherapy). (
  • For this reason, systemic chemotherapy is often used when there is suspicion or significant risk of having widespread cancer cells away from the primary tumor site. (
  • In this case, injecting the drugs directly into the artery can be more effective than systemic chemotherapy. (
  • In the 32 patients treated with IHP alone there were no detectable systemic TNF or melphalan levels during perfusion. (
  • All sixteen patients had received preoperative adjuvant systemic chemotherapy. (
  • Instead, he proposed that breast cancer is a systemic disease that metastasizes unpredictably, and would best be treated with conservative local treatment plus systemic chemotherapy. (
  • Systemic chemotherapy kills or stops cells from dividing throughout the body. (
  • This Phase I study will evaluate the safety of escalating temperatures of continuous hyperthermic peritoneal perfusion (CHPP) with escalating doses of intraperitoneal Cisplatin (CDDP) in the treatment of patients with advanced peritoneal adenocarcinoma of gastrointestinal origin. (
  • The value of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and of additional factors predicting long-term outcome and disease-free survival (DFS) remains poorly understood. (
  • BACKGROUND: Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. (
  • A world-renowned expert in treating peritoneal malignancies with hyperthermic intraperitoneal chemotherapy (HIPEC), Dr. Levine has stated that "Long-term survival is clearly possible for selected patients treated with HIPEC. (
  • Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. (
  • MORGANTOWN, W.Va. - Brian Boone, M.D. , surgical oncologist in the WVU Medicine Department of Surgery and WVU Cancer Institute , performed the state's first hyperthermic intraperitoneal chemotherapy (HIPEC) infusion. (
  • Objective: to present the current state of scientific knowledge about intraoperative hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis, and postoperative nursing care for patients undergoing this therapy. (
  • Methods: the study describes technical aspects of intraoperative hyperthermic intraperitoneal chemotherapy, the potential complications and post-operative nursing care involved. (
  • Conclusion: intraoperative hyperthermic intraperitoneal chemotherapy has been shown to be a promising therapy in treatment of patients with peritoneal carcinomatosis. (
  • Objetivo: presentar el estado del conocimiento científico sobre quimioterapia intraperitoneal hipertérmica transoperatoria en el tratamiento de la carcinomatosis peritoneal y los cuidados de enfermería posoperatorios para pacientes sometidos a ella. (
  • Conclusión: la quimioterapia intraperitoneal hipertérmica transoperatoria es terapia prometedora en el tratamiento de pacientes con carcinomatosis peritoneal. (
  • BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the only curative option for patients with peritoneal carcinomatosis of colorectal origin. (
  • However, promising results have been reported following the implementation of radical cytoreductive surgery followed by transoperativehyperthermic intraperitoneal chemotherapy (HIPEC), which has prolonged survival and has improved the patients' quality of life 2,5,6 . (
  • Seventy-six LGMA patients underwent attempted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). (
  • Citorreductive surgery with hiperthermic intraperitoneal chemotherapy (HIPEC) is associated with an increased long-term survival. (
  • Further studies concerning the application of hyperthermic intraperitoneal chemotherapy (HIPEC) post curative surgery for AGC patients, namely the prophylactic HIPEC (P-HIPEC), have involved a prophylactic approach to prevent peritoneal relapse following curative gastrectomy in high-risk patients. (
  • Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). (
  • Methylation of the genes promoter has been associated with several cancer types, including colorectal cancer, lung cancer, lymphoma and glioblastoma. (
  • Patients eligible for this protocol are those with non-colorectal histologies and those with colorectal cancer previously treated with intra-arterial FUDR. (
  • Histologically or cytologically proven measurable primary or metastatic non-colorectal cancer limited to the parenchyma of the liver with no evidence of unresectable extrahepatic disease by preoperative radiological studies. (
  • Patients with colorectal cancer previously treated with intrahepatic arterial infusional therapy using FUDR, those with aberrant arterial anatomy such that infusional therapy is not possible, or those with limited extrahepatic disease such that regional therapy is not indicated will be eligible for this protocol. (
  • Estimates for the Brazilian population point to 34,280 new cases of colorectal cancer, the second most common type of cancer among women and the third among men, in the biennium 2016-2017 1 . (
  • In this epidemiological context, peritoneal carcinomatosis stands out as a condition associated with the unfavorable prognosis that may be present in the natural history of colorectal cancer and of some other cancers, such as peritoneal pseudomyxoma 2,3 . (
  • Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. (
  • For example, the anti-EGFR monoclonal antibody Cetuximab have been an option for colorectal cancer, while Trastuzumab for breast cancer. (
  • 2008. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK . (
  • IHP can be performed with acceptably low morbidity and has significant antitumor activity in patients with unresectable hepatic metastases from colorectal cancer including those with refractory disease or PHR of 25 or greater. (
  • Richard Alexander, H. / Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer . (
  • Hyperthermia therapy (or hyperthermia, or thermotherapy) is a type of medical treatment in which body tissue is exposed to temperatures in the region of 40-45°C. Hyperthermia is usually applied as an adjuvant to radiotherapy or chemotherapy, to which it works as a sensitizer, in an effort to treat cancer. (
  • This study examines the impact of MIS vs open gastrectomy (OG) on utilization of adjuvant chemotherapy for high-risk gastric cancer. (
  • Primary endpoints were utilization of and time to initiation of adjuvant chemotherapy. (
  • After adjusting for patient and tumor characteristics, MIS was not associated with increased use of adjuvant chemotherapy (odds ratio [OR]: 1.027, 95% confidence interval [CI]: 0.95 to 1.11, P = .50), and time to initiation of chemotherapy was similar (-2% change, 95% CI: -5% to +1%, P = .27). (
  • CONCLUSIONS: In this study, while MIS for gastric adenocarcinoma was associated with shorter hospital stays and comparable survival, it was not associated with improved utilization or time to initiation of adjuvant chemotherapy. (
  • Consequently, Dr. Fisher and his research team demonstrated the superiority of lumpectomy combined with adjuvant chemotherapy as a treatment for breast cancer. (
  • Hyperthermia therapy is a type of medical treatment in which body tissue is exposed to higher temperatures in an effort to treat cancer. (
  • Local hyperthermia heats a very small area and is typically used for cancers near or on the skin or near natural openings in the body (e.g., the mouth). (
  • Regional hyperthermia heats a larger part of the body, such as an entire organ or limb. (
  • This may use the same techniques as local hyperthermia treatment, or it may rely on blood perfusion. (
  • Hyperthermia may be able to decrease the size of cancers. (
  • Tissue damage to a target organ with a regional treatment will vary with what tissue is heated (e.g. brain treated directly may injure the brain, lung tissue treated directly may cause pulmonary problems) Whole body hyperthermia can cause swelling, blood clots, and bleeding. (
  • Research has shown that hyperthermia is able to damage and kill cancer cells. (
  • Localized hyperthermia treatment is a well-established cancer treatment method with a simple basic principle: If a temperature elevation to 40ºC (104ºF) can be maintained for one hour within a cancer tumor, the cancer cells will be destroyed. (
  • The aim of this experimental study was to determine the effect of mild hyperthermia on tumor response and angioneogenesis in an isolated limb perfusion model with a human melanoma xenograft. (
  • In many German and Mexican alternative cancer clinics far infrared saunas are used for thermal therapy, called hyperthermia. (
  • There is a clear rationale for using hyperthermia in cancer treatment. (
  • Isolated hepatic perfusion (IHP) is a regional treatment technique that delivers high dose chemotherapy, biologic agents, and hyperthermia via a completely isolated vascular recirculating perfusion circuit as a means of regionally treating liver tumors. (
  • In fact, hyperthermia, at least in some forms, is now available at a limited number of cancer centers across the United States. (
  • And I know, because I've been an enthusiast for hyperthermia since Cancer Defeated first started in 2005. (
  • Dr. John Hayes, president of Gamma West, said, "We would like to become a regional center of excellence for hyperthermia. (
  • HIPEC is part of a larger regional cancer therapies program at WVU Medicine that includes other procedures that deliver chemotherapy to the areas where it is needed most, including isolated hepatic perfusion and placement of hepatic artery infusion pumps. (
  • therefore, HIPEC can eradicate free cancer cells and micro-metastasis within the peritoneal cavity intraoperatively or soon after curative gastrectomy to reduce peritoneal recurrence. (
  • The selective lethal effect of supranormal temperatures on neoplastic cells and the additive or synergistic effect of combining chemotherapy has been well established in laboratory models and has provided the rationale for numerous clinical trials using hyperthermic isolated limb perfusion for advanced extremity melanoma or sarcoma. (
  • Eggermont AM. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. (
  • High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. (
  • Patients with extremity melanoma (Stage IIIA, IIIAB or Stage IV disease who have bulky symptomatic tumor located in the extremity) or patients with unresectable extremity sarcoma will undergo a double isolated limb perfusion with melphalan alone separated by approximately 4 to 6 weeks. (
  • For patients with extremity sarcoma the tumor will be excised if feasible using a limb sparing resection between 6-12 weeks after the second perfusion. (
  • Cancer is complex - there is no routine soft tissue sarcoma, nor is there ever a routine way to treat it. (
  • The OSUCCC - James is a world leader in soft tissue sarcoma treatment, developing some of the very latest advancements in molecular testing and targeting cancer genes - technology that's available at only a few cancer centers in the country. (
  • At the OSUCCC - James, our soft tissue sarcoma sub-specialists are world-renowned experts who focus solely on sarcoma disorders and who reach across medical disciplines (medical oncologists, surgical oncologists, radiation oncologists, hematologists, pathologists, sarcoma researchers, genomic experts and more) to design the very best treatment plan and therapies to target each patient's specific cancer. (
  • Adult soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. (
  • The cells of each type of sarcoma look different under a microscope , based on the type of soft tissue in which the cancer began. (
  • He is currently the Lead Clinician of The Royal Marsden's Skin Unit as well as Clinical Director of the Rare Cancers Clinical Business Unit, and Co-Chair of the London and South East England Sarcoma Advisory Group . (
  • Isolated limb infusion is a safe and effective technique of treatment of patients with locally advanced soft tissue sarcoma who otherwise might require amputation," said lead study author John E. Mullinax, MD, from Moffitt Cancer Center, Tampa, Fla. (
  • The rationale for amputation of soft tissue sarcoma of the arm or leg has been to prevent the cancer from spreading to, or metastasizing to, other parts of the body. (
  • ILI for soft tissue sarcoma of the extremities can be repeated, whereas another procedure to administer chemotherapy to the arms or legs, hyperthermic isolated limb perfusion, requires an incision to openly cannulate the vessels and generally cannot be repeated, Dr. Mullinax explained. (
  • BACKGROUND: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan is highly effective in treating limb-threatening soft tissue sarcoma (STS) and other bulky tumors. (
  • Localised cancer of soft tissue (sarcoma) in a limb (by regional arterial perfusion only - see 'How is this treatment given? (
  • The malignant form of soft tissue cancer, sarcoma , can also evolve from any of these structures, but is most commonly located in the extremities (arms and legs) and abdomen. (
  • Multimodal therapy often involves regional limb perfusion followed by sarcoma surgery with reconstruction of the resulting defect. (
  • Hyperthermic isolated limb perfusion is an established treatment for multiple, locoregional intransit metastases of malignant melanoma and soft tissue sarcomas of the extremities. (
  • Patients with unresectable primary or metastatic cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) via the portal vein and hepatic artery with escalating dose melphalan. (
  • To treat Melanoma in an arm or leg, chemotherapy drugs may be given as hyperthermic isolated limb perfusion. (
  • It is typically used to treat metastatic cancer (cancer that spread to many parts of the body). (
  • The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer, in May 2014. (
  • Treatment for primary or metastatic liver cancer depends on the location and stage of the cancer and how well liver function is preserved. (
  • Dr. Mullinax noted that one concern with the use of ILI in these cancers is that it does not address distant metastatic disease. (
  • Our initial research focus has been on the treatment of metastatic liver cancers. (
  • Dr. Pingpank will discuss his experience with The Delcath PHP System(TM) and the Company's Phase III Metastatic Melanoma Study, currently enrolling at eleven leading cancer centers throughout the United States. (
  • This clinical study is testing the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. (
  • Dr. Whitman's presentation, titled Percutaneous Isolated Hepatic Perfusion for Cutaneous and Uveal Metastasic Melanoma , will discuss his experience with The Delcath PHP System™, as part of Delcath's multi-center Phase III trial for metastatic melanoma, currently enrolling at twelve leading cancer centers throughout the United States. (
  • It is important to note that the majority of the data was collected based on the pool of patients with mostly advanced and metastatic stage-four cancers. (
  • Regional chemotherapy for the thorax in the form of Isolated Thoracic Perfusion with chemofiltration (ITP-F) is a very effective form of regional chemotherapy for primary and metastatic cancers affecting organs located in that area of the body. (
  • Still others have antiangiogenesis potential, making them a good choice to treat metastatic cancers. (
  • Metastatic and histologic presentations in unknown primary cancer. (
  • A group of Canadian researchers writing in the journal Medical Hypotheses in 2002 stated that Coley's toxins "could induce complete regression of extensive metastatic disease…More than a century after its inception, Coley's vaccine and aggressive approach to treatment may still be one of the most effective immunotherapies for cancer. (
  • To investigate the neural mechanisms underlying attention deficits that are related to neoadjuvant chemotherapy in combination with cerebral perfusion. (
  • Thirty one patients with breast cancer who were scheduled to receive neoadjuvant chemotherapy and 34 healthy control subjects were included. (
  • The patients completed two assessments of the attention network tasks (ANT), neuropsychological background tests, and the arterial spin labeling scan, which were performed before neoadjuvant chemotherapy and after completing chemotherapy. (
  • The results demonstrated that neoadjuvant chemotherapy influences hemodynamic activity in different brain areas through increasing cerebral perfusion, which reduces the attention abilities in breast cancer patients. (
  • The second step for me was Cytoreductive surgery after my neoadjuvant chemotherapy. (
  • To illustrate that Breast-MRI performed in high spatial resolution and low temporal resolution (1 minute) allows the measurement of kinetic parameters that can assess the final pathologic response to neoadjuvant chemotherapy in breast cancer. (
  • Further studies are necessary to confirm whether MRI contrast kinetic parameters can be used earlier as a response predictor to neoadjuvant chemotherapy. (
  • Neoadjuvant chemotherapy is increasingly used in breast cancer patients to decrease the tumour size in large cancers to enable breast-conserving treatment. (
  • Results of regional isolation perfusion with cytostatics in patients with soft-tissue tumors of the extremities. (
  • In addition to being quite rare, cancers and tumors of the appendix come in a wide variety of types. (
  • Radiation oncologists use radiation therapy to attack cancer cells, shrink tumors and provide palliative care for cancer patients. (
  • In addition to his work in developing techniques to deliver targeted chemotherapy to tumor sites, he is also now investigating techniques to deliver gene therapy directly to tumors. (
  • Clinicians and researchers will focus on the state of the art in prevention, recognition, and treatment of cutaneous neoplasms covering melanoma and non melanoma skin cancer as well as lymphomas and rare skin tumors. (
  • However, another option is regional chemotherapy, which targets cancerous tumors in a particular body region via arteries that are feeding the tumor regions. (
  • This capacity of regional chemotherapy often allows to break through drug resistance and is important for treating many types of tumors, including head and neck cancers , lung cancers , ovarian cancer and many other. (
  • specializing in the treatment of cancer tumors using brachytherapy. (
  • Regional perfusion therapy may be a treatment option for tumors resulting from the spread of melanoma that are confined to a single organ or region of the body. (
  • CT perfusion (CTP) is known to provide information about angiogenesis and blood-flow characteristics in tumors. (
  • It can be sued to treat small tumors, minimizing the damage to normal cells or tissue surrounding the tumor, or can be used to destroy cancer cells that remain after surgery. (
  • 1. The treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues. (
  • Medicine) treatment of disease, esp cancer, by means of chemical agents. (
  • The treatment of disease, especially cancer, with chemicals that have a specific poisonous effect on the cancerous or disease-causing cells. (
  • Treatment of disease, especially cancer, and infection using drugs or chemical agents. (
  • Information about the diagnosis and treatment of different cancer types. (
  • Learn about cancer treatments and find your local treatment centre. (
  • Learn about eating well during and after cancer treatment. (
  • Dealing with the ways cancer and treatment may affect your sexuality. (
  • The role of hyperthermic cytostatic perfusion in the treatment of extremity melanoma. (
  • Cancer Care & Treatment Learn about prevention, detection, diagnosis, treatment and more by your cancer type. (
  • Immunotherapy Immunotherapy represents the next frontier of cancer treatment & underscores that no cancer is routine. (
  • Past treatment with radiation therapy for certain cancers. (
  • An in-depth report on the causes, diagnosis, treatment, and prevention of melanoma and nonmelanoma skin cancers. (
  • We offer comprehensive diagnosis and treatment options customized to fit your specific cancer and your personal needs. (
  • With any type of cancer, early detection is critical to successful treatment. (
  • If you are diagnosed with gastrointestinal cancer, your treatment will depend on where your cancer is located and the stage of your cancer. (
  • Main Line Health offers the most advanced treatment options available for all types of gastrointestinal cancer, including minimally invasive techniques that have fewer side effects. (
  • Your treatment may include surgery, chemotherapy , radiation or other techniques, or a combination of multiple treatments. (
  • Chemotherapy - In addition to traditional chemotherapy treatment, we offer long-term infusion chemotherapy treatments and regional perfusion chemotherapy. (
  • Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant? (
  • In combination with other chemotherapy and/or multi-phase treatment regimen for Wilms' tumor. (
  • As a component of regional perfusion, for palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. (
  • Levine continues to research chemotherapy , cancer, regional perfusion, peritoneal neoplasms, and antineoplastic combined chemotherapy, while investigating treatment options through active clinical trials. (
  • For the last eight years, Mr Hayes has also been running a translational research programme in the ICR developing new therapeutic agents to be delivered alongside standard chemotherapy by isolated limb perfusion for the treatment of advanced irresectable limb malignancies. (
  • Treatment for GCC often requires surgery to remove the right side of the colon where the appendix originates, and intravenous chemotherapy. (
  • Of the two cell types, the amount and appearance of the epithelial-derived cancer cells are most important in terms of prognosis and directing treatment. (
  • This treatment delivers heated, sterilized chemotherapy to the abdomen as a treatment for cancer that has spread to the lining of the abdominal cavity, or peritoneum. (
  • It is a treatment option for patients who have advanced surface spread of abdominal cancer that has not spread outside the abdomen. (
  • This treatment allows us to deliver concentrated chemotherapy directly to the affected area without many of the side effects of traditional chemotherapy infusions. (
  • CHICAGO (February 15, 2017): Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option. (
  • The researchers used the treatment technique, known as regional chemotherapy with isolated limb perfusion (ILI), in 77 patients with treatment-resistant, locally advanced soft tissue sarcomas (STS), and were able to salvage limbs in 77.9 percent of the cases. (
  • This treatment method was the first to be based on the concept of isolating an organ (or extremity) and perfusing it with a high dose of chemotherapy. (
  • The treatment of cancer has been transformed by the therapeutic success of "checkpoint blockade," first demonstrated using a neutralizing antibody against CTLA-4, a prototypic negative regulatory molecule that limits T-cell activation. (
  • Localised skin cancer ( malignant melanoma ) affecting a limb (by regional arterial perfusion only - see 'How is this treatment given? (
  • Successful treatment depends on the administration of the next course of therapy before the cancer has regrown to its previous size, with the aimed net effect to decrease the amount of cancer with each successive course of chemotherapy. (
  • Melphalan is mainly used in the treatment of bone marrow cancer (multiple myeloma), but may also sometimes be used to treat advanced cancer of the ovaries or skin cancer. (
  • Long-term treatment with melphalan may increase the risk of developing leukaemia (cancer of the white blood cells) after many years. (
  • This cytotoxic action is the basis for their use in the treatment of certain types of cancer. (
  • This study found that chemotherapy-treated patients had significantly increased post-treatment perfusion in the right precentral gyrus, which was correlated with the baseline of overall neuropsychological performance. (
  • Mesothelioma is an aggressive cancer that needs timely treatment. (
  • They are also aware of the latest innovations in mesothelioma treatment, cancer research and clinical trials. (
  • A specific area of interest to Dr. Bartlett is the research and development of new treatment techniques for patients that have developed cancer in the peritoneal cavity. (
  • He is the author of articles featured in peer reviewed journals, covering topics such as targeted regional treatment and gene therapies. (
  • So what is the latest research in ovarian cancer treatment? (
  • DCTH ) , a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Sixth International Symposium on Melanoma, to be held in New York City on March 13-14, 2009. (
  • Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. (
  • The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. (
  • The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. (
  • Treatment at temperatures between 40 and 44 C is cytotoxic for cells in an environment with a low pO2(oxygen partial pressure) and low pH, conditions that are found specifically within tumour tissue, due to insufficient blood perfusion. (
  • Historically the survival of patients with this disease is less than 12 months without treatment and it is considered a neoplasm resistant to chemotherapy. (
  • BACKGROUND/AIMS: Hepatic arterial infusion chemotherapy (HAIC) has been reported as an effective treatment for advanced hepatocellular carcinoma. (
  • UPMC Hillman Cancer Center offers patients access to the latest advances in cancer prevention, detection, diagnosis, and treatment through cancer clinical trials. (
  • For this reason, regional perfusion therapy may be a treatment option for peritoneal mesothelioma. (
  • Surgical treatment of non-small cell lung cancer (NSCLC) with aortic invasion is still debated. (
  • An important application of IsoFlow may be in the treatment of cancer. (
  • It allows the infusion of fluids into the region and the perfusion of blood past the region to keep the blood flow intact during treatment. (
  • Electrochemotherapy (ECT) with bleomycin as a palliative treatment of regional relapse in head and neck cancer (H&NC) patients (pts). (
  • DCTH ) a medical technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP™) System for the treatment of cancers of the liver, announced today that Eric D. Whitman, MD, Director of the Atlantic Melanoma Center and a Principal Investigator of Delcath's Phase III trial, will present at The 7th World Congress on Melanoma, to be held in Vienna, Austria, May 12-16, 2009. (
  • Early perfusion changes within 1 week after treatment may predict overall survival. (
  • While advances in cancer treatment have come a long way, cancer remains among the leading causes of death worldwide. (
  • Price is among the principal barriers to providing universal access to quality cancer treatment. (
  • Often Regional Chemotherapy cancer treatment outcomes depend upon a number of factors, as does the choice of the therapy. (
  • If standard cancer treatment fails, what's next? (
  • When standard cancer treatment fails, many patients and their families start anew, searching for alternatives. (
  • When standard cancer treatment fails or proves to be insufficient, many patients choose to look beyond standard protocols. (
  • But, how selection of cancer treatment happens? (
  • Selection of the standard cancer treatment depends on the clinicopathologic stage of the disease. (
  • For instance, leucovorin and irinotecan are often chosen for colon cancer treatment, and carboplatin and anthracyclines for breast cancer treatment. (
  • Unfortunately, in some cases standard regimens of cancer treatment fail. (
  • See the PDQ summary on Unusual Cancers of Childhood Treatment for more information on melanoma in children and adolescents. (
  • See the PDQ summary on Skin Cancer Treatment for more information on basal cell and squamous cell skin cancer. (
  • cancer treatment plans based on a combination of nutrition, mind-body techniques, and allopathic medicine. (
  • provides treatment and supportive care to cancer patients and their families in Southeastern Ontario. (
  • offers treatment and therapy for cancer patients and their families. (
  • radiation therapy treatment center for prostate, breast, and other forms of cancer. (
  • state of the art cancer diagnosis and treatment center and support services facility located in Colorado Springs, CO. (
  • 2008. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationship between PSA, pain and quality of life response and survival in the TAX-327 study . (
  • PITTSBURGH, May 10, 2005 - Bernard Fisher, M.D., a pioneer in the biology and treatment of breast cancer, was honored by the University of Pittsburgh with a special lecture and portrait unveiling. (
  • His work changed the course of treatment, the rate of survival and the quality of life for women with breast cancer," said Dr. Levine. (
  • At a time when radical mastectomy was the standard treatment for breast cancer, Dr. Fisher's landmark research found that less extensive and less disfiguring procedures were just as effective. (
  • His findings set a revolutionary new course for the treatment not only of breast cancer but other types of cancer as well. (
  • It's important to learn as much as you can about the nature of your cancer and your treatment options and to make the decision that's right for you. (
  • Regional chemotherapy is directed at a specific part of the body, focusing the treatment there and sparing normal cells from damage. (
  • In Acharya tulsi regional cancer treatment and research institute Bikaner hospital squamous cell carcinoma interpretation for 15% of all cases of NSCLC according to registry. (
  • Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. (
  • In fact, our physician experts actually help write the national clinical guidelines for treating specific cancers. (
  • He is Head of the Skin Unit and Clinical Director for the Rare Cancers Clinical Business Unit at The Royal Marsden NHS Foundation Trust. (
  • Dr. David Bartlett is the director of Multidisciplinary Disease Site Clinical and Research Programs for UPMC Hillman Cancer Center in Pennsylvania . (
  • The Phase III clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. (
  • Find here all the information related to anti-cancer agents as described in the ESMO Handbook on Clinical Pharmacology of Anti-Cancer Agents. (
  • Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20:6406-17. (
  • The aim of this study was to observe the clinical efficacy and side effects of verapamil combined with antitumor drugs via Pleural Catheter Perfusion (PCC). (
  • 2008. Clinical benefit and quality life in patients with advanced pancreatic cancer receiving Gemcitabine plus Capecitabine versus Gemcitabine alone: a multicenter phase III clinical trial SAKK 44/00-CECOG/PAN 1.3.001 . (
  • Although our numbers are small, we believe that there is no clinical evidence justifying hesitation or refusal of free flap reconstruction after limb perfusion and intraarterial chemotherapy. (
  • At least 2 months since any regional therapy to the affected extremity. (
  • Although the most frequent cause of death after curative resection of advanced gastric cancer is peritoneal recurrence, there was no effective therapy for the prevention of peritoneal recurrence. (
  • The patient may receive radiation therapy or chemotherapy before surgery to shrink the tumor. (
  • Radiation therapy uses high-energy X-rays or other radiation to kill cancer cells or keep them from growing. (
  • Postoperative radiation therapy is used to destroy any potentially remaining cancer cells. (
  • Intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS) - These advanced radiation techniques enable you to receive targeted therapy at the site of your cancer. (
  • PURPOSE: Preoperative therapy in borderline resectable pancreatic cancer (BRPC) is intended to increase R0 resection rates. (
  • By the mid-1990s, the need for a minimally invasive method to accomplish organ isolation and perfusion was met by Delcath's development of chemosaturation therapy via percutaneous hepatic perfusion (PHP). (
  • In an extremity perfusion model in tumor-bearing rats, we measured response rates to TNF therapy. (
  • Results of the TNF perfusions in rats suggest that this tumor is more sensitive to TNF therapy. (
  • Together, our findings suggest that local chemotherapy combined with checkpoint blockade-based immunotherapy results in a durable response to cancer therapy. (
  • Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to the liver perfusion and must have recovered from all side effects. (
  • As such, ASL is a promising technique to assess whether therapy-induced cerebral perfusion changes could explain the cognitive impairments in patients with breast cancer after chemotherapy. (
  • Medical oncologists use chemotherapy drugs, targeted therapy, hormonal therapy, immunotherapy and biological therapy to treat cancer. (
  • NorthShore is only one of several centers of excellence in the United States to provide regional therapy for advanced or recurrent soft tissue sarcomas that may not be amenable to surgery. (
  • In addition to working at the Cancer Center, Dr. Bartlett is the Bernard Fisher Professor of Surgery at the University of Pittsburgh School of Medicine, vice chairman for surgical oncology and gastrointestinal services and vice chairman of the David C. Koch Regional Perfusion Cancer Therapy Center on the UPMC campus. (
  • The following excerpts are from recent studies on the effects of far infrared and thermal therapy (hyperthermeia) on cancer. (
  • Systematic chemotherapy or targeted therapy have not been able to significantly reduce the major cause of an unfavorable prognosis, namely the high peritoneal AGC recurrence rate post-surgery. (
  • Thirteen patients with locally advanced (T4) NSCLC and invasion of the descending aorta underwent pneumonectomy (n=9) or lobectomy (n=4) together with aorta en bloc resection and reconstruction (n=8) or subadventitial dissection (n=5), complete lymph node dissection, and had microscopic unsuspected node metastasis at N1 (n=5) and N2/3 (n=8) levels of whom 12 received radiation therapy. (
  • Learn more about UPMC Hillman Cancer Center's David C. Koch Regional Perfusion Cancer Therapy Center . (
  • Deng GL, Zeng S, Shen H (2015) Chemotherapy and target therapy for hepatocellular carcinoma: new advances and challenges. (
  • What has the impact of the programmes like the FDA's Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review been on the availability of cancer drugs, and can these models be applied to other aspects of cancer care? (
  • Multimodal therapy including intraarterial chemotherapy is recognized as state-of-the art therapy for soft-tissue cancer. (
  • It's most potent when used in combination with an intravenous therapy such as low-dose chemotherapy, laetrile (often used in Mexico) or mistletoe extract (the anti-cancer remedy that's a German favorite). (
  • It is entirely fitting that one pioneer in breast cancer research be invited to recognize the work of another," said David L. Bartlett, M.D., chief of the division of surgical oncology and director, David C. Koch Regional Perfusion Cancer Therapy Center at UPMC Cancer Centers . (
  • Melanoma can be treated through one or more of the following: surgery, chemotherapy, radiation therapy, as well as new investigative treatments such as biologic therapy or chemoimmunotherapy. (
  • Radiation therapy uses high-energy, pinpointed x-rays to kill cancer cells. (
  • Biologic therapy uses the natural defenses of the immune system to fight cancer. (
  • Chemoimmunotherapy uses anti-cancer drugs along the biologic therapy to boost the immune system. (
  • Dr. Pingpank's presentation is titled Targeting the Liver: Percutaneous Hepatic Perfusion/Intra-Arterial . (
  • Regional chemotherapy was given through a vein grafted between the common carotid and external carotid arteries to 20 patients who had a variety of advanced head and neck cancers. (
  • Isolated limb perfusion in primary and recurrent melanoma: indications and results. (
  • Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients: a review of its indications and the role of tumour necrosis factor-alpha. (
  • Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. (
  • Isolated limb perfusion for malignant melanoma. (
  • Isolated limb perfusion achieves local tumor control in a high percentage of cases. (
  • He leads the Isolated Limb Perfusion programme, which provides a national service for regional chemotherapy for patients with advanced limb malignancy. (
  • Regional chemotherapy delivery techniques began in the mid-20th century with isolated limb perfusion (ILP) performed to treat melanoma. (
  • Alkeran injection can also be given via a procedure called regional arterial perfusion or isolated limb perfusion, to treat melanomas or sarcomas affecting a localised area of a limb, eg arm or leg. (
  • These techniques include isolated limb infusion and isolated limb perfusion. (
  • A retrospective chart review of 52 patients who had undergone limb perfusion between 1988 and 1998 at the University of Texas M. D. Anderson Cancer Center and the Division of Plastic Surgery, University of Bochum, Germany, identified 16 patients who had undergone intraarterial limb perfusion that was then followed by surgical resection and free flap reconstruction. (
  • The disease has a marked propensity for loco-regional spread and will be the sole or major site of disease in up to 80% of patients. (
  • Specifically, patients with gastric cancer and bulky N-2 lymph node involvement or patients with other primaries and who have malignant ascites or peritoneal seeding would be considered optimal candidates. (
  • Stages according to the American Joint Committee on Cancer classification were II (19 patients), III (78 patients), and IV (3 patients). (
  • This randomized trial sought to determine whether intraoperative chemohyperthermic peritoneal perfusion could eliminate microscopic residual disease and thereby improve survival of patients with advanced gastric cancer. (
  • One-hundred and thirty-nine patients with T2-4 gastric cancer underwent curative gastrectomy with extended lymphadenectomy. (
  • Patients in the CHPP group received surgery + chemohyperthermic peritoneal perfusion, and those in the CNPP group underwent surgery + chemonormothermic peritoneal perfusion. (
  • In a subset analysis, patients with gastric cancer having serosal invasion or lymph node metastasis have shown a statistically significant improvement in survival when treated with chemohyperthermic peritoneal perfusion. (
  • Chemohyperthermic peritoneal perfusion had an efficiency for the prophylaxis of recurrence after curative resection of advanced gastric cancer, and is indicated for patients with tumor infiltrating beyond serosal layer and node positive tumor. (
  • HOPE Program Learn more about peer support for cancer patients and caregivers. (
  • Advocacy Be an advocate for cancer patients, research and care. (
  • Esophagectomy - We offers trans hiatal and minimally invasive esophagectomy for patients with high-grade dysplasia (swallowing problems) or early cancer. (
  • In patients with primary liver cancer, surgical removal with curative intent may be possible. (
  • Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. (
  • Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. (
  • As a single agent or as part of a combination chemotherapy regimen for post-menarchal patients with gestational trophoblastic neoplasia. (
  • BACKGROUND: Chemotherapy improves outcomes in patients with resectable gastric cancer. (
  • METHODS: Patients in the National Cancer Database who underwent resection for high-risk gastric adenocarcinoma between 2010 and 2015 were included. (
  • MATERIALS AND METHODS: Patients with gastric adenocarcinoma from the National Cancer Database from 2004 to 2015 were examined retrospectively. (
  • Because of fear of TNF-associated toxicity, ILP with TNF is not offered to older patients in some cancer centers, although especially in older patients, every attempt to avoid an amputation that may end their independence must be considered. (
  • 75 years old after leakage-free perfusions and were not related to TNF but to extremely high-risk profiles in these three patients. (
  • This approach has produced durable antitumor responses in patients with melanoma, lung cancer, kidney cancer, and ovarian cancer ( 1, 2 ). (
  • 0.01 corrected) when compared with patients before chemotherapy and healthy controls. (
  • A significant correlation was found between the decrease performance of ANT and the increase in CBF changes in some brain regions of the patients with breast cancer. (
  • We recently reported findings from a cross-sectional neuropsychological study that the chemotherapy-treated breast cancer patients had significant impairment of attention networks 6 . (
  • These physicians usually end up referring patients to oncologists for a cancer examination. (
  • Surgical oncologists perform surgeries to help patients with all forms of mesothelioma and other cancers. (
  • He has also assisted with developing a technique to deliver chemotherapy directly into the peritoneal cavity in patients that present with localized malignancies in that region. (
  • Dr. Bartlett has conducted research at the National Cancer Institute to develop new surgical techniques that resulted in improved survival rates for patients with cancer of the abdomen and liver. (
  • The determination of residual tumour size is underestimated and unreliable in carcinomas significantly responding to chemotherapy which may lead to missed detections in up to 30% of patients [ 6 ]. (
  • A preoperative ostomy and an ASA score of 3 were associated with an increased risk for "open and close" (O&C). Median survival was 11.2 months in patients treated with palliative chemotherapy (75 %) compared with 2.7 months with palliative care only. (
  • Survival in these patients is limited, but the majority could be treated with palliative chemotherapy resulting in survival of almost 1 year. (
  • The Mario Lemieux Center for Blood Cancers offers personalized treatments for patients with all types of blood cancer. (
  • The effect of intravenous hyperalimentation on the dietary intake of patients with small cell lung cancer. (
  • Correlation of thyroglobulin measurements and radioiodine scans in the follow-up of patients with differentiated thyroid cancer. (
  • Survival of cancer patients by economic status in a free care setting. (
  • provides treatments for patients with cancer and blood disorders. (
  • From December 2004 to December 2014, a total of 79 patients with non-encapsulated MPE were treated in our department, who were all applied standardized chemotherapy while failed or recurred. (
  • 2008. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer . (
  • 18F]FDG-PET/CT imaging is broadly used in head and neck cancer (HNSCC) patients. (
  • I said then, and I've often said since, this is among the top ten alternative therapies that cancer patients should seek out. (
  • For centuries, spontaneous tumor regression has been observed in cancer patients suffering from malaria, influenza or any infectious disease that causes a fever of around 104ºF. (
  • In the late 19th century, New York surgeon William Coley noticed this, and developed a method of inducing severe bacterial infections in cancer patients to create a fever and rev up the immune system. (
  • All techniques are often combined with radiation or chemotherapy, muddying how much toxicity is the result of those treatments versus the temperature elevation achieved. (
  • We also use targeted radiation treatments that help preserve your healthy tissue while destroying cancer cells. (
  • How can combination therapies help merge new immunotherapies and traditional therapies yield more targeted, effective, cancer treatments? (
  • Researches are taking into consideration directions to reach more cancer-selective approaches to treatments. (
  • provides total care for cancer and blood disorders throughout the Atlanta metro area with conventional treatments as well as as mind-body and nutritional therapies. (
  • offers alternative cancer treatments for various forms of the disease. (
  • One of my top 10 cancer treatments slowly becomes available in the U.S. (
  • Regional hepatic arterial delivery of high-dose chemotherapy with isolated hepatic perfusion used to be done using open surgical techniques, which carried a risk of significant morbidity and mortality. (
  • We are always looking for ways to treat cancer without increasing the health burden on the patient," Carl Schmidt, M.D. , surgical oncologist and surgeon-in-chief at the WVU Cancer Institute, said. (
  • Investigators at the National Cancer Institute (NCI) and elsewhere refined these surgical methods to completely isolate the liver and to establish a recirculating vascular perfusion circuit. (
  • His primary research interests include radiographic imaging of gynecological cancers, the surgical management of cancers of the ovary and endometrium, the patterns of healthcare delivery per women with gynecological cancer among others. (
  • Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. (
  • Improving survival for less common and low survival cancers. (
  • However, chemonormothermic peritoneal perfusion had no survival benefit. (
  • By analyzing with Cox proportional hazard model, chemohyperthermic peritoneal perfusion emerged as an independent prognostic factor for good survival. (
  • Aortic resection with single station node positive T4 lung cancer can achieve long-term survival. (
  • 2008. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study . (
  • In advanced lung cancer chemotherapy play main role in quality of life and survival. (
  • One specialized type of this approach is continuous hyperthermic peritoneal perfusion (CHPP), which is used to treat difficult cancers within the peritoneal cavity (the abdomen), including primary peritoneal mesothelioma and stomach cancer. (
  • Hot chemotherapy drugs are pumped directly into the peritoneal cavity to kill the cancer cells. (
  • This study examines the outcomes of urgent versus elective surgery for gastric cancer. (
  • Advanced gastric cancer (AGC) has a high recurrence rate (especially peritoneal relapse) and a poor prognosis. (
  • In women, they often spread to the ovaries and can be easily confused with ovarian cancer. (
  • Finding GCC that have already spread at the time of diagnosis is more common in women and 15-30% are initially diagnosed as having an ovarian cancer. (
  • So since Ovarian cancer and Peritoneal Cancer are both treated with the same drugs, my oncologist's first option was a chemo cocktail of Carboplatin and Paclitaxel (Taxol). (
  • Since I've been living with Peritoneal Carcinomatosis/Ovarian Cancer Stage IV since my diagnosis in November of 2012, I've been through a lot. (
  • According to the American Cancer Society over 21,000 new cases of ovarian cancer are diagnosed each year with 15,000 more women dying from it annually. (
  • Dr. Bristow is Director of the Kelly Gynecology Oncology Service in the John Hopkins Ovarian Cancer Center of Excellence. (
  • Why is ovarian cancer so difficult to treat? (
  • There is a lot of interest in ovarian cancer research because it is the most lethal of the all the gynecologic cancers predominantly as a result of presenting in an advanced stage, so there are a number of very high-quality researchers across the country and indeed across the world that have devoted their entire professional careers to ovarian cancer research and it is really directed at multiple angles. (
  • You know, physicians that are within my specialty of gynecologic oncology have at a minimum had three additional years of training beyond the usual OB/GYN Residency Program where we specifically focus on treating nothing but gynecologic cancer and the surgeries for a woman with advanced ovarian cancer are oftentimes are extensive procedures and quite complex. (
  • Meet Tracy Palmer, a breast cancer survivor. (
  • DNA-damaging chemicals, formed when meat is cooked, stimulate breast cancer cells almost as much as pure estrogen and can infiltrate the ducts where most breast cancers arise. (
  • Influence of oral contraceptives on the prognosis of breast cancer in young women. (
  • The 2005 Bernard Fisher Lecture was presented by Mary-Claire King, Ph.D., a leading scientist who discovered the first genetic link to breast cancer. (
  • Dr. Fisher is known for overturning the prevailing paradigm that breast cancer metastasizes in an orderly and sequential fashion. (
  • His later studies showed that the drug tamoxifen can substantially reduce the risk of breast cancer in high-risk women who have not yet developed this disease. (
  • Dr. King, who presented the Fisher Lecture on March 29, is best known for discovering that mutations in a single gene known as BRCA1 can cause hereditary breast cancer. (
  • Prior to her work, the popular view was that unknown genes and environmental factors caused breast cancer. (
  • This, in turn, made it possible for the gene's location to be found and led to the development of breast cancer testing, screening and prophylactic procedures, while providing new insights into the nature of cancer-causing genetic mutations. (
  • The Isolated Thoracic Perfusion (ITP) is used in order to simultaneously include all of the blood vessels that supply those tumours, in order to treat the recurrent breast cacner. (
  • However, cancer occurs more often as a result of metastases from other sites such as the lung, colon, stomach and eye (particularly ocular melanoma). (
  • Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion. (
  • Gemcitabine has been used as the first-line drug for advance pancreatic cancer for over two decades and combinations of gemcitabine with different chemotherapeutic drugs have been investigated to improve the outcomes of pancreatic cancer. (
  • The investigators will analyze and evaluate the effect and safety of an implanted percutaneous left subclavian artery port-catheter drug delivery system for regional chemotherapy of inoperable pancreatic carcinoma. (
  • Impact of variant pancreatic arterial anatomy and overlap in regional perfusion on the interpretation of selective arterial calcium stimulation with hepatic venous sampling for preoperative localization of occult insulinoma. (
  • Surgery alone had three-fold higher risk of death than chemohyperthermic peritoneal perfusion. (
  • Regional hyperthermic perfusion with melphalan after surgery for recurrent melanoma of the extremities. (
  • If the GCC has spread in the abdomen, additional surgery to remove the cancer and heated chemotherapy delivered directly into the abdomen may be considered. (
  • Melphalan can be used alone, or in combination with other anti-cancer medicines or surgery. (
  • He is board certified in general surgery and specializes in treating peritoneal mesothelioma and other carcinomas that develop in the peritoneal region, such as liver and bile duct cancer and abdominal sarcomas. (
  • However, when I went to the University of Pittsburgh Medical Center for a SECOND opinion, exploratory surgery and a PET scan revealed cancer in both my ovaries. (
  • Often, the first step in treating liver cancer is surgery to remove as much of the tumor as possible. (
  • Isolated liver perfusion , which delivers chemotherapy directly to the liver through an open surgery. (
  • Contact us about liver cancer surgery options at UPMC Hillman Cancer Center at 412-647-2811 . (
  • Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. (
  • A wide variety of single agent and combination chemotherapy regimens with Cosmegen have been studied. (
  • If there is a recurrence following combination chemotherapy with platinum-containing agents, life expectancy is poor. (
  • This form of regional chemotherapy has significant advantages over the conventional form that uses durgs given through the retrograde temporal artery because the catheter-related complications are eliminated, the perfusion of the tumor can be maintained consistently, and, consequently, the response rate is high and the duration of response is increased. (
  • Minimally invasive gastrectomy (MIS) rates are increasing, though the impact of MIS on postoperative chemotherapy remains uncertain. (
  • Patient received cisplatin and gemcitabine chemotherapy. (
  • However, once the cancer cells escape from the appendix, they can continue to grow in the abdominal cavity, on the surface of other organs such as the omentum, intestines, ovaries, uterus, liver, spleen and peritoneum (lining of the abdominal cavity). (
  • This condition is called peritoneal carcinomatosis (see Related Disorders) - which means growth of cancer cells within the abdominal cavity. (
  • Peritoneal mesothelioma is a cancer that forms in the lining of the abdominal cavity. (
  • Later, in the 1980s and 1990s, isolated hepatic perfusion (IHP) expanded the concept of regional high-dose chemotherapy to the liver. (
  • A pathologist views the tissue under a microscope to look for cancer cells and to find out the grade of the tumor. (
  • Endoscopic ultrasound with fine needle aspiration - This test takes a biopsy (tissue sample) to test for cancer. (
  • The functional analysis is based on post-therapeutic changes of microvessels permeability, tissue perfusion, blood volume, and extracellular leakage space. (
  • Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. (
  • The "fever" kills cancer cells, while leaving healthy tissue unharmed. (
  • In blood perfusion, the patient's blood is removed from the body, heated up, and returned to blood vessels that lead directly through the desired body part. (
  • Usually, the goal is to weaken cancer cells so that they are more likely to be killed by radiation and chemotherapeutic medications. (
  • At NorthShore, our cancer surgeons have expertise to treat this disease and work collaboratively with plastic surgeons, radiation oncologists and medical oncologists . (
  • Based on the type of cell in which they originate, skin cancers are divided into two major groups: melanoma and non-melanoma skin cancers. (
  • The "World Congress on Melanoma" and the "Congress of the European Association of Dermato-Oncology" (EADO) have become major interdisciplinary meetings for clinicians and basic scientists working in the challenging fields of melanoma and non-melanoma skin cancer. (
  • The most skilled mesothelioma doctors are typically affiliated with major cancer centers and universities throughout the United States. (
  • not for profit, tax-exempt corporation that is an alliance of cancer centers. (
  • Hepatic arterial infusion (HAI) pump, which uses an implanted pump to deliver chemotherapy directly to the liver. (